|
特拉华州
|
| |
13-1840497
|
|
|
(州或其他司法管辖区)
公司或组织) |
| |
(国税局雇主识别号)
|
|
|
Glenpointe Center East,3楼
300 Frank W.Burr Boulevard,Suite 21 Teaneck,新泽西州 (主要执行办公室地址) |
| |
07666-6712
(邮政编码) |
|
|
每一类的名称
|
| |
交易符号
|
| |
每间交易所的注册名称
|
|
|
A类普通股,0.0001美元
每股面值 |
| |
PAHC
|
| |
纳斯达克股票市场
|
|
| 大型加速滤波器 | | | ☐ | | | | | | 加速填报器 | | | | |
| 非加速报税器 | | | ☐ | | | | | | 小型报表公司 | | | ☐ | |
| 新兴成长型公司 | | | ☐ | | | | | | | | | | |
| | |
页
|
| |||
前瞻性陈述
|
| | | | 3 | | |
市场排名和其他行业数据
|
| | | | 4 | | |
商标、服务标记和商品名称
|
| | | | 5 | | |
第一部分 | | ||||||
Item 1.
Business
|
| | | | 6 | | |
Item 1A.
Risk Factors
|
| | | | 25 | | |
Item 1B.
Unresolved Staff Comments
|
| | | | 50 | | |
Item 2.
Properties
|
| | | | 50 | | |
Item 3.
Legal Proceedings
|
| | | | 51 | | |
Item 4.
Mine Safety Disclosures
|
| | | | 51 | | |
第二部分 | | ||||||
Item 5.
登记人普通股、相关股东事项和股票证券发行人购买市场
|
| | | | 52 | | |
Item 6.
Selected Financial Data
|
| | | | 54 | | |
Item 7.
管理层对财务状况和经营结果的讨论和分析
|
| | | | 56 | | |
Item 7A.
关于市场风险的定量和定性披露
|
| | | | 78 | | |
Item 8.
财务报表及补充数据
|
| | | | 80 | | |
Item 9.
会计人员在会计和财务披露方面的变化和分歧
|
| | | | 119 | | |
Item 9A.
Controls and Procedures
|
| | | | 119 | | |
Item 9B.
Other Information
|
| | | | 120 | | |
第三部分 | | ||||||
Item 10.
董事、高管和公司治理
|
| | | | 121 | | |
Item 11.
Executive Compensation
|
| | | | 121 | | |
Item 12.
某些实益所有者的安全所有权和管理层及相关股东事宜
|
| | | | 121 | | |
Item 13.
某些关系和相关交易,以及董事独立性
|
| | | | 121 | | |
Item 14.
主要会计费用和服务
|
| | | | 121 | | |
第四部分 | | ||||||
Item 15.
展品,财务报表明细表
|
| | | | 122 | | |
SIGNATURES
|
| | | | 123 | | |
| | |
分段
|
| |
变化
|
| |
占总数的百分比
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||
For the Year Ended June 30
|
| |
2019
|
| |
2018
|
| |
2017
|
| |
2019/2018
|
| |
2018/2017
|
| |
2019
|
| |
2018
|
| |
2017
|
| ||||||||||||||||||||||||||||||||||||
| | |
(百万美元)
|
| | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
动物健康
|
| | | $ | 532 | | | | | $ | 532 | | | | | $ | 498 | | | | | $ | 0 | | | | |
|
0%
|
| | | | $ | 34 | | | | |
|
7%
|
| | | |
|
64%
|
| | | |
|
65%
|
| | | |
|
65%
|
| |
矿质营养
|
| | | | 234 | | | | | | 235 | | | | | | 218 | | | | | | (1) | | | | |
|
(0)%
|
| | | | | 17 | | | | |
|
8%
|
| | | |
|
28%
|
| | | |
|
29%
|
| | | |
|
29%
|
| |
性能产品
|
| | | | 62 | | | | | | 53 | | | | | | 48 | | | | | | 9 | | | | |
|
17%
|
| | | | | 5 | | | | |
|
11%
|
| | | |
|
8%
|
| | | |
|
7%
|
| | | |
|
6%
|
| |
总计
|
| | | $ | 828 | | | | | $ | 820 | | | | | $ | 764 | | | | | $ | 8 | | | | |
|
1%
|
| | | | $ | 56 | | | | |
|
7%
|
| | | | |
| | |
种
|
| |
变化
|
| |
占总数的百分比
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||
For the Year Ended June 30
|
| |
2019
|
| |
2018
|
| |
2017
|
| |
2019/2018
|
| |
2018/2017
|
| |
2019
|
| |
2018
|
| |
2017
|
| ||||||||||||||||||||||||||||||||||||
| | |
(百万美元)
|
| | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
家禽
|
| | | $ | 316 | | | | | $ | 321 | | | | | $ | 301 | | | | | $ | (5) | | | | |
|
(2)%
|
| | | | $ | 20 | | | | |
|
7%
|
| | | |
|
38%
|
| | | |
|
39%
|
| | | |
|
39%
|
| |
乳品
|
| | | | 170 | | | | | | 177 | | | | | | 157 | | | | | | (7) | | | | |
|
(4)%
|
| | | | | 20 | | | | |
|
13%
|
| | | |
|
21%
|
| | | |
|
22%
|
| | | |
|
21%
|
| |
黄牛
|
| | | | 88 | | | | | | 80 | | | | | | 76 | | | | | | 8 | | | | |
|
10%
|
| | | | | 4 | | | | |
|
5%
|
| | | |
|
11%
|
| | | |
|
10%
|
| | | |
|
10%
|
| |
猪
|
| | | | 101 | | | | | | 100 | | | | | | 93 | | | | | | 1 | | | | |
|
1%
|
| | | | | 7 | | | | |
|
8%
|
| | | |
|
12%
|
| | | |
|
12%
|
| | | |
|
12%
|
| |
其他(1) | | | | | 153 | | | | | | 142 | | | | | | 137 | | | | | | 11 | | | | |
|
8%
|
| | | | | 5 | | | | |
|
4%
|
| | | |
|
18%
|
| | | |
|
17%
|
| | | |
|
18%
|
| |
总计
|
| | | $ | 828 | | | | | $ | 820 | | | | | $ | 764 | | | | | $ | 8 | | | | |
|
1%
|
| | | | $ | 56 | | | | |
|
7%
|
| | | | | |||||||||||||||
|
| | |
区域(2)
|
| |
变化
|
| |
占总数的百分比
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||
For the Year Ended June 30
|
| |
2019
|
| |
2018
|
| |
2017
|
| |
2019/2018
|
| |
2018/2017
|
| |
2019
|
| |
2018
|
| |
2017
|
| ||||||||||||||||||||||||||||||||||||
| | |
(百万美元)
|
| | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
美国
|
| | | $ | 481 | | | | | $ | 491 | | | | | $ | 484 | | | | | $ | (10) | | | | |
|
(2)%
|
| | | | $ | 7 | | | | |
|
1%
|
| | | |
|
58%
|
| | | |
|
60%
|
| | | |
|
63%
|
| |
拉丁美洲和加拿大
|
| | | | 152 | | | | | | 143 | | | | | | 113 | | | | | | 9 | | | | |
|
6%
|
| | | | | 30 | | | | |
|
27%
|
| | | |
|
18%
|
| | | |
|
17%
|
| | | |
|
15%
|
| |
欧洲、中东和非洲
|
| | | | 105 | | | | | | 110 | | | | | | 96 | | | | | | (5) | | | | |
|
(5)%
|
| | | | | 14 | | | | |
|
15%
|
| | | |
|
13%
|
| | | |
|
13%
|
| | | |
|
13%
|
| |
亚太
|
| | | | 90 | | | | | | 76 | | | | | | 71 | | | | | | 14 | | | | |
|
18%
|
| | | | | 5 | | | | |
|
7%
|
| | | |
|
11%
|
| | | |
|
9%
|
| | | |
|
9%
|
| |
总计
|
| | | $ | 828 | | | | | $ | 820 | | | | | $ | 764 | | | | | $ | 8 | | | | |
|
1%
|
| | | | $ | 56 | | | | |
|
7%
|
| | | | |
| | |
调整后的EBITDA(1)
|
| |
变化
|
| |
占总数的百分比(2)
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||
For the Year Ended June 30
|
| |
2019
|
| |
2018
|
| |
2017
|
| |
2019/2018
|
| |
2018/2017
|
| |
2019
|
| |
2018
|
| |
2017
|
| ||||||||||||||||||||||||||||||||||||
| | |
(百万美元)
|
| | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
动物健康
|
| | | $ | 136 | | | | | $ | 142 | | | | | $ | 130 | | | | | $ | (6) | | | | |
|
(4)%
|
| | | | $ | 12 | | | | |
|
9%
|
| | | |
|
87%
|
| | | |
|
87%
|
| | | |
|
87%
|
| |
矿质营养
|
| | | | 16 | | | | | | 19 | | | | | | 17 | | | | | | (3) | | | | |
|
(15)%
|
| | | | | 1 | | | | |
|
7%
|
| | | |
|
10%
|
| | | |
|
11%
|
| | | |
|
12%
|
| |
性能产品
|
| | | | 5 | | | | | | 2 | | | | | | 2 | | | | | | 3 | | | | |
|
151%
|
| | | | | (0) | | | | |
|
(9)%
|
| | | |
|
3%
|
| | | |
|
1%
|
| | | |
|
1%
|
| |
公司
|
| | | | (38) | | | | | | (33) | | | | | | (30) | | | | | | (5) | | | | |
|
*
|
| | | | | (4) | | | | |
|
*
|
| | | | | |||||||||||||||
总计
|
| | | $ | 118 | | | | | $ | 129 | | | | | $ | 120 | | | | | $ | (11) | | | | |
|
(8)%
|
| | | | $ | 9 | | | | |
|
7%
|
| | | | |
| | |
可识别资产净值
|
| |
变化
|
| |
占总数的百分比
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||
As of June 30
|
| |
2019
|
| |
2018
|
| |
2017
|
| |
2019/2018
|
| |
2018/2017
|
| |
2019
|
| |
2018
|
| |
2017
|
| ||||||||||||||||||||||||||||||||||||
| | |
(百万美元)
|
| | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
动物健康
|
| | | $ | 509 | | | | | $ | 456 | | | | | $ | 442 | | | | | $ | 53 | | | | |
|
12%
|
| | | | $ | 14 | | | | |
|
3%
|
| | | |
|
70%
|
| | | |
|
68%
|
| | | |
|
71%
|
| |
矿质营养
|
| | | | 68 | | | | | | 70 | | | | | | 55 | | | | | | (2) | | | | |
|
(3)%
|
| | | | | 15 | | | | |
|
26%
|
| | | |
|
9%
|
| | | |
|
10%
|
| | | |
|
9%
|
| |
性能产品
|
| | | | 33 | | | | | | 24 | | | | | | 24 | | | | | | 9 | | | | |
|
37%
|
| | | | | 0 | | | | |
|
1%
|
| | | |
|
5%
|
| | | |
|
4%
|
| | | |
|
4%
|
| |
公司
|
| | | | 117 | | | | | | 122 | | | | | | 102 | | | | | | (5) | | | | |
|
(4)%
|
| | | | | 20 | | | | |
|
20%
|
| | | |
|
16%
|
| | | |
|
18%
|
| | | |
|
16%
|
| |
总计
|
| | | $ | 727 | | | | | $ | 672 | | | | | $ | 623 | | | | | $ | 54 | | | | |
|
8%
|
| | | | $ | 49 | | | | |
|
8%
|
| | | | | |||||||||||||||
|
| | |
产品组
|
| |
变化
|
| |
占总数的百分比
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||
For the Year Ended June 30
|
| |
2019
|
| |
2018
|
| |
2017
|
| |
2019/2018
|
| |
2018/2017
|
| |
2019
|
| |
2018
|
| |
2017
|
| ||||||||||||||||||||||||||||||||||||
| | |
(百万美元)
|
| | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
MFA和其他
|
| | | $ | 350 | | | | | $ | 337 | | | | | $ | 321 | | | | | $ | 13 | | | | |
|
4%
|
| | | | $ | 16 | | | | |
|
5%
|
| | | |
|
66%
|
| | | |
|
63%
|
| | | |
|
65%
|
| |
营养专科
|
| | | | 113 | | | | | | 123 | | | | | | 111 | | | | | | (10) | | | | |
|
(8)%
|
| | | | | 12 | | | | |
|
11%
|
| | | |
|
21%
|
| | | |
|
23%
|
| | | |
|
22%
|
| |
疫苗
|
| | | | 68 | | | | | | 72 | | | | | | 65 | | | | | | (4) | | | | |
|
(5)%
|
| | | | | 7 | | | | |
|
11%
|
| | | |
|
13%
|
| | | |
|
14%
|
| | | |
|
13%
|
| |
动物健康
|
| | | $ | 532 | | | | | $ | 532 | | | | | $ | 498 | | | | | $ | (0) | | | | |
|
(0)%
|
| | | | $ | 34 | | | | |
|
7%
|
| | | | | |||||||||||||||
|
| | |
区域(1)
|
| |
变化
|
| |
占总数的百分比
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||
For the Years Ended June 30
|
| |
2019
|
| |
2018
|
| |
2017
|
| |
2019/2018
|
| |
2018/2017
|
| |
2019
|
| |
2018
|
| |
2017
|
| ||||||||||||||||||||||||||||||||||||
| | |
(百万美元)
|
| | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
美国
|
| | | $ | 199 | | | | | $ | 220 | | | | | $ | 230 | | | | | $ | (21) | | | | |
|
(10)%
|
| | | | $ | (10) | | | | |
|
(4)%
|
| | | |
|
37%
|
| | | |
|
41%
|
| | | |
|
46%
|
| |
拉丁美洲和加拿大
|
| | | | 142 | | | | | | 129 | | | | | | 104 | | | | | | 13 | | | | |
|
10%
|
| | | | | 25 | | | | |
|
24%
|
| | | |
|
27%
|
| | | |
|
24%
|
| | | |
|
21%
|
| |
欧洲、中东和非洲
|
| | | | 103 | | | | | | 108 | | | | | | 93 | | | | | | (5) | | | | |
|
(5)%
|
| | | | | 15 | | | | |
|
16%
|
| | | |
|
19%
|
| | | |
|
20%
|
| | | |
|
19%
|
| |
亚太
|
| | | | 88 | | | | | | 75 | | | | | | 71 | | | | | | 13 | | | | |
|
17%
|
| | | | | 4 | | | | |
|
6%
|
| | | |
|
17%
|
| | | |
|
14%
|
| | | |
|
14%
|
| |
总计
|
| | | $ | 532 | | | | | $ | 532 | | | | | $ | 498 | | | | | $ | — | | | | |
|
0%
|
| | | | $ | 34 | | | | |
|
7%
|
| | | | |
产品
|
| |
有效成分
|
| |
市场进入
有效成分 |
| |
描述
|
|
Terramycin®/TM-50®/TM-100™ | | | 土霉素 | | |
1951
|
| | 抗菌有多种用途,适用于多种物种 | |
尼加拉瓜® | | | 尼加拉瓜 | | |
1954
|
| | 家禽抗球虫 | |
氨丙啉 | | | 氨丙啉 | | |
1960
|
| | 家禽和牛用抗球虫 | |
膨胀防护(BLOAT Guard®) | | | 聚草烯 | | |
1967
|
| | 牛的消肿治疗 | |
Banminth® | | | 酒石酸吡喃酮 | | |
1972
|
| | 牲畜驱虫剂 | |
Mecadox® | | | 卡巴多 | | |
1972
|
| | 猪抗菌控制沙门氏菌病和痢疾 | |
STAFAC®/Eskalin™/V-MAX® | | | 维吉尼亚霉素 | | |
1975
|
| | 用于预防和控制家禽、猪和牛的疾病的抗菌剂 | |
Coxistac™/Posistac™ | | | 盐霉素 | | |
1979
|
| | 家禽牛猪抗球虫 | |
Rumatel® | | | 酒石酸莫兰特 | | |
1981
|
| | 牲畜驱虫剂 | |
Cerditac™/CerdiMix™ | | | 奥西苯达唑 | | |
1982
|
| | 牲畜驱虫剂 | |
产品
|
| |
有效成分
|
| |
市场进入
有效成分 |
| |
描述
|
|
Aviax® | | | 半硬膜霉素 | | |
1995
|
| | 家禽抗球虫 | |
NEO-Terramycin®/NEO-TM™ | | | 土霉素+新霉素 | | |
1999
|
| | 两种抗菌药的组合,具有多种用途,适用于多种物种 | |
Aviax®Plus/Avi-Carb® | | | Semduramicin+尼加拉瓜 | | |
2010
|
| | 家禽抗球虫 | |
产品
|
| |
市场
入口 |
| |
描述
|
|
AB20® | | |
1989
|
| | 提高饲料整体质量的天然流动剂 | |
Animate® | | |
1999
|
| | 在关键过渡期维持奶牛适当的血钙水平 | |
Omnigen-AF® | | |
2004
|
| | 优化奶牛的免疫状态 | |
Provia 6086™ | | |
2013
|
| | 所有类别牲畜的直接饲喂微生物(凝固性芽孢杆菌) | |
Magni-Phi® | | |
2015
|
| | 有助于提高免疫反应并可能改善家禽对营养物质的吸收和利用的专有混合物 | |
Cellerate酵母解决方案® | | |
2017
|
| | 所有类别牲畜的专有酵母培养产品,帮助改善消化健康 | |
Provia Prime™ | | |
2019
|
| | 4路组合直接饲喂微生物优化家禽肠道健康 | |
产品
|
| |
市场
入口 |
| |
描述
|
|
V.H.® | | |
1974
|
| | 预防家禽新城疫的活疫苗 | |
定制®疫苗 | | |
1982
|
| | 针对家禽、猪和牛的细菌性或病毒性疾病的自体疫苗 | |
MVP佐剂® | | |
1982
|
| | 增强疫苗免疫应答的兽用疫苗成分 | |
TAbic®M.B. | | |
2004
|
| | 预防家禽传染性法氏囊病的活疫苗 | |
MJPRRS® | | |
2007
|
| | 预防猪繁殖与呼吸综合征(PRRS)的自体疫苗 | |
TAbic®IB VAR | | |
2009
|
| | 家禽传染性支气管炎变异体1株233A活疫苗的研究 | |
TAbic®IB VAR206 | | |
2010
|
| | 预防家禽传染性支气管炎变异体206活疫苗 | |
MB-1TM | | |
2017
|
| | 预防家禽传染性法氏囊病的孵化活疫苗 | |
Phi-TechTM | | |
2019
|
| | 便携式电子注射装置,能够管理和正确提供疫苗 | |
业务部门
|
| |
定位
|
| |
拥有/租赁
|
| |
大约。SQ。
镜头 |
| |
目的
|
|
动物健康 | | | 贝特·谢梅什(Beit Shemesh),以色列 | | | 拥有/土地租赁 | | |
78,000
|
| | 制造和研究 | |
动物健康 | | | 布拉甘卡·保利斯塔(Braganca Paulista),巴西 | | | 拥有 | | |
50,000
|
| | 制造和管理 | |
动物健康 | | | 阿根廷布宜诺斯艾利斯 | | | 拥有 | | |
43,000
|
| | 制造和管理 | |
动物健康 | | | 奇里科斯,伊利诺伊州 | | | 拥有 | | |
19,000
|
| | 制造业 | |
动物健康 | | | 科瓦利斯,俄勒冈州 | | | 拥有 | | |
5,000
|
| | 研究 | |
动物健康 | | | 瓜鲁霍斯,巴西 | | | 拥有 | | |
1,294,000
|
| | 制造,销售,预混,研究和行政 | |
动物健康 | | | Neot Hovav,以色列 | | | 拥有/土地租赁 | | |
140,000
|
| | 制造和研究 | |
矿质营养 | | | 内布拉斯加州奥马哈 | | | 拥有 | | |
84,000
|
| | 制造业 | |
动物健康 | | | 内布拉斯加州奥马哈 | | | 拥有 | | |
43,000
|
| | 制造、销售和研究 | |
动物健康 | | | Petach Tikva,以色列 | | | 拥有 | | |
60,000
|
| | 制造业 | |
业务部门
|
| |
定位
|
| |
拥有/租赁
|
| |
大约。SQ。
镜头 |
| |
目的
|
|
动物健康与矿物质营养 | | | 昆西,伊利诺伊州 | | | 拥有 | | |
306,000
|
| | 制造、销售、研究和管理 | |
性能产品 | | |
圣达菲温泉,加利福尼亚州
|
| | 拥有 | | |
108,000
|
| | 制造业 | |
动物健康 | | |
宾夕法尼亚州州立学院
|
| | 拥有 | | |
13,000
|
| | 研究 | |
动物健康 | | | 明尼苏达州圣保罗 | | | 租赁 | | |
5,000
|
| | 研究 | |
公司 | | | Teaneck,新泽西州 | | | 租赁 | | |
50,000
|
| | 公司和行政 | |
For the Year Ended June 30
|
| |
2019
|
| |
2018
|
| |
2017
|
| |
2016
|
| |
2015
|
| |||||||||||||||
| | |
(以千计,每股金额除外)
|
| |||||||||||||||||||||||||||
操作结果数据 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
净销售额
|
| | | $ | 827,995 | | | | | $ | 819,982 | | | | | $ | 764,281 | | | | | $ | 751,526 | | | | | $ | 748,591 | | |
销售商品成本
|
| | | | 563,371 | | | | | | 553,103 | | | | | | 516,038 | | | | | | 512,494 | | | | | | 515,311 | | |
毛利
|
| | | | 264,624 | | | | | | 266,879 | | | | | | 248,243 | | | | | | 239,032 | | | | | | 233,280 | | |
销售,一般和管理费用
|
| | | | 181,398 | | | | | | 167,953 | | | | | | 150,309 | | | | | | 153,288 | | | | | | 145,612 | | |
营业收入
|
| | | | 83,226 | | | | | | 98,926 | | | | | | 97,934 | | | | | | 85,744 | | | | | | 87,668 | | |
利息费用,净额
|
| | | | 11,776 | | | | | | 11,910 | | | | | | 14,906 | | | | | | 16,592 | | | | | | 14,305 | | |
外币(收益)损失,净额
|
| | | | (55) | | | | | | (1,054) | | | | | | (113) | | | | | | (7,609) | | | | | | (5,400) | | |
清偿债务损失
|
| | | | — | | | | | | — | | | | | | 2,598 | | | | | | — | | | | | | — | | |
所得税前收入
|
| | | | 71,505 | | | | | | 88,070 | | | | | | 80,543 | | | | | | 76,761 | | | | | | 78,763 | | |
为所得税准备(利益)
|
| | | | 16,792 | | | | | | 23,187 | | | | | | 15,928 | | | | | | (5,967) | | | | | | 18,483 | | |
净收入
|
| | | $ | 54,713 | | | | | $ | 64,883 | | | | | $ | 64,615 | | | | | $ | 82,728 | | | | | $ | 60,280 | | |
每股净收益 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
基本型
|
| | | $ | 1.35 | | | | | $ | 1.61 | | | | | $ | 1.63 | | | | | $ | 2.11 | | | | | $ | 1.55 | | |
稀释
|
| | | $ | 1.35 | | | | | $ | 1.61 | | | | | $ | 1.61 | | | | | $ | 2.07 | | | | | $ | 1.51 | | |
加权平均已发行普通股 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
基本型
|
| | | | 40,412 | | | | | | 40,181 | | | | | | 39,524 | | | | | | 39,254 | | | | | | 38,969 | | |
稀释
|
| | | | 40,523 | | | | | | 40,385 | | | | | | 40,042 | | | | | | 39,962 | | | | | | 39,815 | | |
每股股息
|
| | | $ | 0.46 | | | | | $ | 0.40 | | | | | $ | 0.40 | | | | | $ | 0.40 | | | | | $ | 0.40 | | |
其他财务数据 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
调整后的EBITDA(1)
|
| | | $ | 118,037 | | | | | $ | 128,958 | | | | | $ | 120,119 | | | | | $ | 114,060 | | | | | $ | 110,019 | | |
经营活动提供的现金(2)
|
| | | | 47,169 | | | | | | 70,008 | | | | | | 98,385 | | | | | | 37,218 | | | | | | 68,704 | | |
资本支出
|
| | | | 29,891 | | | | | | 18,548 | | | | | | 20,880 | | | | | | 36,352 | | | | | | 20,058 | | |
For the Year Ended June 30
|
| |
2019
|
| |
2018
|
| |
2017
|
| |
2016
|
| |
2015
|
| |||||||||||||||
| | |
(千)
|
| |||||||||||||||||||||||||||
资产负债表数据 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
现金和现金等价物和短期投资
|
| | | $ | 81,573 | | | | | $ | 79,168 | | | | | $ | 56,083 | | | | | $ | 33,605 | | | | | $ | 29,216 | | |
营运资金(3)
|
| | | | 242,902 | | | | | | 205,651 | | | | | | 198,036 | | | | | | 203,356 | | | | | | 175,988 | | |
总资产
|
| | | | 726,671 | | | | | | 671,679 | | | | | | 623,397 | | | | | | 607,835 | | | | | | 490,250 | | |
债务总额(4)
|
| | | | 326,175 | | | | | | 312,381 | | | | | | 313,141 | | | | | | 350,172 | | | | | | 286,450 | | |
长期债务及其他负债
|
| | | | 356,429 | | | | | | 343,504 | | | | | | 356,444 | | | | | | 408,578 | | | | | | 349,185 | | |
股东权益总额
|
| | | | 216,015 | | | | | | 184,954 | | | | | | 151,157 | | | | | | 90,480 | | | | | | 29,628 | | |
For the Year Ended June 30
|
| |
2019
|
| |
2018
|
| |
2017
|
| |
2016
|
| |
2015
|
| |||||||||||||||
| | |
(千)
|
| |||||||||||||||||||||||||||
净收入
|
| | | $ | 54,713 | | | | | $ | 64,883 | | | | | $ | 64,615 | | | | | $ | 82,728 | | | | | $ | 60,280 | | |
另加: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
利息费用,净额
|
| | | | 11,776 | | | | | | 11,910 | | | | | | 14,906 | | | | | | 16,592 | | | | | | 14,305 | | |
为所得税准备(利益)
|
| | | | 16,792 | | | | | | 23,187 | | | | | | 15,928 | | | | | | (5,967) | | | | | | 18,483 | | |
折旧摊销
|
| | | | 27,564 | | | | | | 26,943 | | | | | | 26,001 | | | | | | 23,452 | | | | | | 21,604 | | |
EBITDA
|
| | | | 110,845 | | | | | | 126,923 | | | | | | 121,450 | | | | | | 116,805 | | | | | | 114,672 | | |
重组成本
|
| | | | 6,281 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
股票薪酬
|
| | | | 2,259 | | | | | | 334 | | | | | | — | | | | | | — | | | | | | — | | |
与收购相关的销售商品成本
|
| | | | — | | | | | | 1,671 | | | | | | — | | | | | | 2,566 | | | | | | — | | |
与收购相关的应计补偿
|
| | | | — | | | | | | 1,152 | | | | | | 1,680 | | | | | | 1,680 | | | | | | 747 | | |
与收购相关的交易成本
|
| | | | 213 | | | | | | 400 | | | | | | 1,274 | | | | | | 618 | | | | | | — | | |
与收购相关的其他,净
|
| | | | — | | | | | | (468) | | | | | | (972) | | | | | | — | | | | | | — | | |
其他
|
| | | | (1,506) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
养老金结算成本
|
| | | | — | | | | | | — | | | | | | 1,702 | | | | | | — | | | | | | — | | |
保险结算收益
|
| | | | — | | | | | | — | | | | | | (7,500) | | | | | | — | | | | | | — | | |
外币(收益)损失,净额
|
| | | | (55) | | | | | | (1,054) | | | | | | (113) | | | | | | (7,609) | | | | | | (5,400) | | |
清偿债务损失
|
| | | | — | | | | | | — | | | | | | 2,598 | | | | | | — | | | | | | — | | |
调整后EBITDA
|
| | | $ | 118,037 | | | | | $ | 128,958 | | | | | $ | 120,119 | | | | | $ | 114,060 | | | | | $ | 110,019 | | |
For the Year Ended June 30
|
| |
2019
|
| |
2018
|
| |
2017
|
| |
2016
|
| |
2015
|
| |||||||||||||||
| | |
(千)
|
| |||||||||||||||||||||||||||
EBITDA
|
| | | $ | 110,845 | | | | | $ | 126,923 | | | | | $ | 121,450 | | | | | $ | 116,805 | | | | | $ | 114,672 | | |
调整数 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
重组成本
|
| | | | 6,281 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
股票薪酬
|
| | | | 2,259 | | | | | | 334 | | | | | | — | | | | | | — | | | | | | — | | |
与收购相关的销售商品成本
|
| | | | — | | | | | | 1,671 | | | | | | — | | | | | | 2,566 | | | | | | — | | |
与收购相关的应计补偿
|
| | | | — | | | | | | 1,152 | | | | | | 1,680 | | | | | | 1,680 | | | | | | 747 | | |
与收购相关的交易成本
|
| | | | 213 | | | | | | 400 | | | | | | 1,274 | | | | | | 618 | | | | | | — | | |
与收购相关的其他,净
|
| | | | — | | | | | | (468) | | | | | | (972) | | | | | | — | | | | | | — | | |
其他
|
| | | | (1,506) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
养老金结算成本
|
| | | | — | | | | | | — | | | | | | 1,702 | | | | | | — | | | | | | — | | |
保险结算收益
|
| | | | — | | | | | | — | | | | | | (7,500) | | | | | | — | | | | | | — | | |
外币(收益)损失,净额
|
| | | | (55) | | | | | | (1,054) | | | | | | (113) | | | | | | (7,609) | | | | | | (5,400) | | |
清偿债务损失
|
| | | | — | | | | | | — | | | | | | 2,598 | | | | | | — | | | | | | — | | |
已付利息
|
| | | | (12,250) | | | | | | (11,208) | | | | | | (14,600) | | | | | | (14,215) | | | | | | (12,912) | | |
缴纳所得税
|
| | | | (16,215) | | | | | | (15,191) | | | | | | (14,762) | | | | | | (16,828) | | | | | | (10,780) | | |
营业资产和负债及其他项目的变化
|
| | | | (42,190) | | | | | | (32,151) | | | | | | 1,402 | | | | | | (45,181) | | | | | | (12,337) | | |
由/(用于)保险结算/(索赔)提供的现金
|
| | | | — | | | | | | — | | | | | | 7,500 | | | | | | — | | | | | | (5,286) | | |
用于收购相关交易成本的现金
|
| | | | (213) | | | | | | (400) | | | | | | (1,274) | | | | | | (618) | | | | | | — | | |
经营活动提供的净现金
|
| | | $ | 47,169 | | | | | $ | 70,008 | | | | | $ | 98,385 | | | | | $ | 37,218 | | | | | $ | 68,704 | | |
| | | | | |
变化
|
| ||||||||||||||||||||||||||||||||||||
For the Year Ended June 30
|
| |
2019
|
| |
2018
|
| |
2017
|
| |
2019/2018
|
| |
2018/2017
|
| |||||||||||||||||||||||||||
| | |
(以千计,每股除外)
|
| |||||||||||||||||||||||||||||||||||||||
净销售额
|
| | | $ | 827,995 | | | | | $ | 819,982 | | | | | $ | 764,281 | | | | | $ | 8,013 | | | | |
|
1%
|
| | | | $ | 55,701 | | | | |
|
7%
|
| |
毛利
|
| | | | 264,624 | | | | | | 266,879 | | | | | | 248,243 | | | | | | (2,255) | | | | |
|
(1)%
|
| | | | | 18,636 | | | | |
|
8%
|
| |
销售,一般和管理费用
|
| | | | 181,398 | | | | | | 167,953 | | | | | | 150,309 | | | | | | 13,445 | | | | |
|
8%
|
| | | | | 17,644 | | | | |
|
12%
|
| |
营业收入
|
| | | | 83,226 | | | | | | 98,926 | | | | | | 97,934 | | | | | | (15,700) | | | | |
|
(16)%
|
| | | | | 992 | | | | |
|
1%
|
| |
利息费用,净额
|
| | | | 11,776 | | | | | | 11,910 | | | | | | 14,906 | | | | | | (134) | | | | |
|
(1)%
|
| | | | | (2,996) | | | | |
|
(20)%
|
| |
外币(收益)损失,
网 |
| | | | (55) | | | | | | (1,054) | | | | | | (113) | | | | | | 999 | | | | |
|
*
|
| | | | | (941) | | | | |
|
*
|
| |
清偿债务损失
|
| | | | — | | | | | | — | | | | | | 2,598 | | | | | | — | | | | | | * | | | | | | (2,598) | | | | | | * | | |
所得税前收入
|
| | | | 71,505 | | | | | | 88,070 | | | | | | 80,543 | | | | | | (16,565) | | | | |
|
(19)%
|
| | | | | 7,527 | | | | |
|
9%
|
| |
所得税准备金
|
| | | | 16,792 | | | | | | 23,187 | | | | | | 15,928 | | | | | | (6,395) | | | | |
|
(28)%
|
| | | | | 7,259 | | | | |
|
46%
|
| |
净收入
|
| | | $ | 54,713 | | | | | $ | 64,883 | | | | | $ | 64,615 | | | | | $ | (10,170) | | | | |
|
(16)%
|
| | | | $ | 268 | | | | |
|
0%
|
| |
每股净收益 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
基本型
|
| | | $ | 1.35 | | | | | $ | 1.61 | | | | | $ | 1.63 | | | | | $ | (0.26) | | | | | | | | | | | $ | (0.02) | | | | | | | | |
稀释
|
| | | $ | 1.35 | | | | | $ | 1.61 | | | | | $ | 1.61 | | | | | $ | (0.26) | | | | | | | | | | | $ | — | | | | | | | | |
加权平均股数
出类拔萃 |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
基本型
|
| | | | 40,412 | | | | | | 40,181 | | | | | | 39,524 | | | | | | | | | | | | | | | | | | | | | | | | | | |
稀释
|
| | | | 40,523 | | | | | | 40,385 | | | | | | 40,042 | | | | | | | | | | | | | | | | | | | | | | | | | | |
净销售额比率 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
毛利
|
| | | | 32.0% | | | | | | 32.5% | | | | | | 32.5% | | | | | | | | | | | | | | | | | | | | | | | | | | |
销售,一般和管理费用
|
| | |
|
21.9%
|
| | | |
|
20.5%
|
| | | |
|
19.7%
|
| | | | | | | | | | | | | | | | | | | | | | | | | |
营业收入
|
| | | | 10.1% | | | | | | 12.1% | | | | | | 12.8% | | | | | | | | | | | | | | | | | | | | | | | | | | |
所得税前收入
|
| | | | 8.6% | | | | | | 10.7% | | | | | | 10.5% | | | | | | | | | | | | | | | | | | | | | | | | | | |
净收入
|
| | | | 6.6% | | | | | | 7.9% | | | | | | 8.5% | | | | | | | | | | | | | | | | | | | | | | | | | | |
有效税率
|
| | | | 23.5% | | | | | | 26.3% | | | | | | 19.8% | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | |
变化
|
| ||||||||||||||||||||||||||||||||||||
For the Year Ended June 30
|
| |
2019
|
| |
2018
|
| |
2017
|
| |
2019/2018
|
| |
2018/2017
|
| |||||||||||||||||||||||||||
| | |
(千)
|
| |||||||||||||||||||||||||||||||||||||||
Net sales | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
MFA和其他
|
| | | $ | 350,468 | | | | | $ | 336,666 | | | | | $ | 321,430 | | | | | $ | 13,802 | | | | |
|
4%
|
| | | | $ | 15,236 | | | | |
|
5%
|
| |
营养专科
|
| | | | 113,215 | | | | | | 122,978 | | | | | | 111,282 | | | | | | (9,763) | | | | |
|
(8)%
|
| | | | | 11,696 | | | | |
|
11%
|
| |
疫苗
|
| | | | 68,291 | | | | | | 72,083 | | | | | | 65,033 | | | | | | (3,792) | | | | |
|
(5)%
|
| | | | | 7,050 | | | | |
|
11%
|
| |
动物健康
|
| | | | 531,974 | | | | | | 531,727 | | | | | | 497,745 | | | | | | 247 | | | | |
|
0%
|
| | | | | 33,982 | | | | |
|
7%
|
| |
矿质营养
|
| | | | 233,782 | | | | | | 234,922 | | | | | | 218,298 | | | | | | (1,140) | | | | |
|
(0)%
|
| | | | | 16,624 | | | | |
|
8%
|
| |
性能产品
|
| | | | 62,239 | | | | | | 53,333 | | | | | | 48,238 | | | | | | 8,906 | | | | |
|
17%
|
| | | | | 5,095 | | | | |
|
11%
|
| |
总计
|
| | | $ | 827,995 | | | | | $ | 819,982 | | | | | $ | 764,281 | | | | | $ | 8,013 | | | | |
|
1%
|
| | | | $ | 55,701 | | | | |
|
7%
|
| |
调整的EBITDA | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
动物健康
|
| | | $ | 136,049 | | | | | $ | 141,914 | | | | | $ | 130,261 | | | | | $ | (5,865) | | | | |
|
(4)%
|
| | | | $ | 11,653 | | | | |
|
9%
|
| |
矿质营养
|
| | | | 15,712 | | | | | | 18,583 | | | | | | 17,426 | | | | | | (2,871) | | | | |
|
(15)%
|
| | | | | 1,157 | | | | |
|
7%
|
| |
性能产品
|
| | | | 4,728 | | | | | | 1,881 | | | | | | 2,057 | | | | | | 2,847 | | | | |
|
151%
|
| | | | | (176) | | | | |
|
(9)%
|
| |
公司
|
| | | | (38,452) | | | | | | (33,420) | | | | | | (29,625) | | | | | | (5,032) | | | | |
|
*
|
| | | | | (3,795) | | | | |
|
*
|
| |
总计
|
| | | $ | 118,037 | | | | | $ | 128,958 | | | | | $ | 120,119 | | | | | $ | (10,921) | | | | |
|
(8)%
|
| | | | $ | 8,839 | | | | |
|
7%
|
| |
调整后的EBITDA比率与部门净销售额之比
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
动物健康
|
| | | | 25.6% | | | | | | 26.7% | | | | | | 26.2% | | | | | | | | | | | | | | | | | | | | | | | | | | |
矿质营养
|
| | | | 6.7% | | | | | | 7.9% | | | | | | 8.0% | | | | | | | | | | | | | | | | | | | | | | | | | | |
性能产品
|
| | | | 7.6% | | | | | | 3.5% | | | | | | 4.3% | | | | | | | | | | | | | | | | | | | | | | | | | | |
公司(1)
|
| | |
|
(4.6)%
|
| | | |
|
(4.1)%
|
| | | |
|
(3.9)%
|
| | | | | | | | | | | | | | | | | | | | | | | | | |
总计(1)
|
| | |
|
14.3%
|
| | | |
|
15.7%
|
| | | |
|
15.7%
|
| | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | |
变化
|
| ||||||||||||||||||||||||||||||||||||
For the Year Ended June 30
|
| |
2019
|
| |
2018
|
| |
2017
|
| |
2019/2018
|
| |
2018/2017
|
| |||||||||||||||||||||||||||
| | |
(千)
|
| |||||||||||||||||||||||||||||||||||||||
净收入
|
| | | $ | 54,713 | | | | | $ | 64,883 | | | | | $ | 64,615 | | | | | $ | (10,170) | | | | |
|
(16)%
|
| | | | $ | 268 | | | | |
|
0%
|
| |
利息费用,净额
|
| | | | 11,776 | | | | | | 11,910 | | | | | | 14,906 | | | | | | (134) | | | | |
|
(1)%
|
| | | | | (2,996) | | | | |
|
(20)%
|
| |
所得税准备金
|
| | | | 16,792 | | | | | | 23,187 | | | | | | 15,928 | | | | | | (6,395) | | | | |
|
(28)%
|
| | | | | 7,259 | | | | |
|
46%
|
| |
折旧摊销
|
| | | | 27,564 | | | | | | 26,943 | | | | | | 26,001 | | | | | | 621 | | | | |
|
2%
|
| | | | | 942 | | | | |
|
4%
|
| |
EBITDA
|
| | | | 110,845 | | | | | | 126,923 | | | | | | 121,450 | | | | | | (16,078) | | | | |
|
(13)%
|
| | | | | 5,473 | | | | |
|
5%
|
| |
重组成本
|
| | | | 6,281 | | | | | | — | | | | | | — | | | | | | 6,281 | | | | |
|
*
|
| | | | | — | | | | |
|
*
|
| |
股票薪酬
|
| | | | 2,259 | | | | | | 334 | | | | | | — | | | | | | 1,925 | | | | |
|
576%
|
| | | | | 334 | | | | |
|
*
|
| |
与收购相关的销售商品成本
|
| | | | — | | | | | | 1,671 | | | | | | — | | | | | | (1,671) | | | | |
|
*
|
| | | | | 1,671 | | | | |
|
*
|
| |
与收购相关的应计补偿
|
| | | | — | | | | | | 1,152 | | | | | | 1,680 | | | | | | (1,152) | | | | |
|
*
|
| | | | | (528) | | | | |
|
(31)%
|
| |
与收购相关的交易成本
|
| | | | 213 | | | | | | 400 | | | | | | 1,274 | | | | | | (187) | | | | |
|
(47)%
|
| | | | | (874) | | | | |
|
(69)%
|
| |
与收购相关的其他,净额(1)
|
| | | | — | | | | | | (468) | | | | | | (972) | | | | | | 468 | | | | |
|
*
|
| | | | | 504 | | | | |
|
*
|
| |
其他,净
|
| | | | (1,506) | | | | | | — | | | | | | — | | | | | | (1,506) | | | | |
|
*
|
| | | | | — | | | | |
|
*
|
| |
养老金结算费用
|
| | | | — | | | | | | — | | | | | | 1,702 | | | | | | — | | | | |
|
*
|
| | | | | (1,702) | | | | |
|
*
|
| |
保险结算收益
|
| | | | — | | | | | | — | | | | | | (7,500) | | | | | | — | | | | |
|
*
|
| | | | | 7,500 | | | | |
|
*
|
| |
外币(收益)损失,
网 |
| | | | (55) | | | | | | (1,054) | | | | | | (113) | | | | | | 999 | | | | |
|
*
|
| | | | | (941) | | | | |
|
*
|
| |
清偿债务损失
|
| | | | — | | | | | | — | | | | | | 2,598 | | | | | | — | | | | |
|
*
|
| | | | | (2,598) | | | | |
|
*
|
| |
调整后EBITDA
|
| | | $ | 118,037 | | | | | $ | 128,958 | | | | | $ | 120,119 | | | | | $ | (10,921) | | | | |
|
(8)%
|
| | | | $ | 8,839 | | | | |
|
7%
|
| |
For the Year Ended June 30
|
| |
2019
|
| |
2018
|
| ||||||
| | |
(以千计,不包括百分比)
|
| |||||||||
所得税准备金
|
| | | $ | 16,792 | | | | | $ | 23,187 | | |
有效所得税税率
|
| | | | 23.5% | | | | | | 26.3% | | |
某些所得税项目 | | | | | | | | | | | | | |
从行使的员工股票期权中受益
|
| | | $ | (310) | | | | | $ | (3,773) | | |
强制使用费
|
| | | | (360) | | | | | | 403 | | |
国内递延税金资产减少
|
| | | | — | | | | | | 2,289 | | |
减少国外递延税金资产
|
| | | | — | | | | | | 1,156 | | |
承认联邦和外国税收抵免
|
| | | | (1,417) | | | | | | (565) | | |
从累计的其他综合收入重新分类
|
| | | | — | | | | | | 527 | | |
释放未确认的税收优惠
|
| | | | (1,271) | | | | | | (994) | | |
总计
|
| | | $ | (3,358) | | | | | $ | (957) | | |
所得税准备金,不包括某些项目
|
| | | $ | 20,150 | | | | | $ | 24,144 | | |
有效所得税税率,不包括某些项目
|
| | | | 28.2% | | | | | | 27.4% | | |
For the Year Ended June 30
|
| |
2018
|
| |
2017
|
| ||||||
| | |
(以千计,不包括百分比)
|
| |||||||||
所得税准备金
|
| | | $ | 23,187 | | | | | $ | 15,928 | | |
有效所得税税率
|
| | |
|
26.3%
|
| | | |
|
19.8%
|
| |
某些所得税项目 | | | | | | | | | | | | | |
从行使的员工股票期权中受益。
|
| | | $ | (3,773) | | | | | $ | (3,096) | | |
强制使用费
|
| | | | 403 | | | | | | — | | |
国内递延税金资产减少
|
| | | | 2,289 | | | | | | — | | |
减少国外递延税金资产
|
| | | | 1,156 | | | | | | — | | |
承认外国税收抵免
|
| | | | (565) | | | | | | — | | |
从累计的其他综合收入重新分类
|
| | | | 527 | | | | | | — | | |
释放未确认的税收优惠
|
| | | | (994) | | | | | | (500) | | |
放行外国估价津贴
|
| | | | — | | | | | | (4,118) | | |
总计
|
| | | $ | (957) | | | | | $ | (7,714) | | |
所得税准备金,不包括某些项目
|
| | | $ | 24,144 | | | | | $ | 23,642 | | |
有效所得税税率,不包括某些项目
|
| | |
|
27.4%
|
| | | |
|
29.3%
|
| |
| | | | | |
变化
|
| ||||||||||||||||||||||||
For the Year Ended June 30
|
| |
2019
|
| |
2018
|
| |
2017
|
| |
2019/2018
|
| |
2018/2017
|
| |||||||||||||||
| | |
(千)
|
| |||||||||||||||||||||||||||
提供的现金/(用于): | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
经营活动
|
| | | $ | 47,169 | | | | | $ | 70,008 | | | | | $ | 98,385 | | | | | $ | (22,839) | | | | | $ | (28,377) | | |
投资活动
|
| | | | (14,133) | | | | | | (84,612) | | | | | | (21,942) | | | | | | 70,479 | | | | | | (62,670) | | |
融资活动
|
| | | | (4,107) | | | | | | (11,775) | | | | | | (53,738) | | | | | | 7,668 | | | | | | 41,963 | | |
汇率变动对现金及现金等价物的影响
|
| | | | (524) | | | | | | (536) | | | | | | (227) | | | | | | 12 | | | | | | (309) | | |
现金及现金等价物净增加/(减少)
|
| | | $ | 28,405 | | | | | $ | (26,915) | | | | | $ | 22,478 | | | | | $ | 55,320 | | | | | $ | (49,393) | | |
| | | | | |
变化
|
| ||||||||||||||||||||||||
For the Year Ended June 30
|
| |
2019
|
| |
2018
|
| |
2017
|
| |
2019/2018
|
| |
2018/2017
|
| |||||||||||||||
| | |
(千)
|
| |||||||||||||||||||||||||||
EBITDA
|
| | | $ | 110,845 | | | | | $ | 126,923 | | | | | $ | 121,450 | | | | | $ | (16,078) | | | | | $ | 5,473 | | |
调整数
|
| | | | | | |||||||||||||||||||||||||
重组成本
|
| | | | 6,281 | | | | | | — | | | | | | — | | | | | | 6,281 | | | | | | — | | |
股票薪酬
|
| | | | 2,259 | | | | | | 334 | | | | | | — | | | | | | 1,925 | | | | | | 334 | | |
与收购相关的销售商品成本
|
| | | | — | | | | | | 1,671 | | | | | | — | | | | | | (1,671) | | | | | | 1,671 | | |
与收购相关的应计补偿
|
| | | | — | | | | | | 1,152 | | | | | | 1,680 | | | | | | (1,152) | | | | | | (528) | | |
与收购相关的交易成本
|
| | | | 213 | | | | | | 400 | | | | | | 1,274 | | | | | | (187) | | | | | | (874) | | |
与收购相关的其他,净
|
| | | | — | | | | | | (468) | | | | | | (972) | | | | | | 468 | | | | | | 504 | | |
其他,净
|
| | | | (1,506) | | | | | | — | | | | | | — | | | | | | (1,506) | | | | | | — | | |
养老金结算成本
|
| | | | — | | | | | | — | | | | | | 1,702 | | | | | | — | | | | | | (1,702) | | |
保险结算收益
|
| | | | — | | | | | | — | | | | | | (7,500) | | | | | | — | | | | | | 7,500 | | |
外币(收益)损失,净额
|
| | | | (55) | | | | | | (1,054) | | | | | | (113) | | | | | | 999 | | | | | | (941) | | |
清偿债务损失
|
| | | | — | | | | | | — | | | | | | 2,598 | | | | | | — | | | | | | (2,598) | | |
已付利息
|
| | | | (12,250) | | | | | | (11,208) | | | | | | (14,600) | | | | | | (1,042) | | | | | | 3,392 | | |
缴纳所得税
|
| | | | (16,215) | | | | | | (15,191) | | | | | | (14,762) | | | | | | (1,024) | | | | | | (429) | | |
营业资产和负债及其他项目的变化
|
| | | | (42,190) | | | | | | (32,151) | | | | | | 1,402 | | | | | | (10,039) | | | | | | (33,553) | | |
保险结算提供的现金
|
| | | | — | | | | | | — | | | | | | 7,500 | | | | | | — | | | | | | (7,500) | | |
用于收购相关交易成本的现金
|
| | | | (213) | | | | | | (400) | | | | | | (1,274) | | | | | | 187 | | | | | | 874 | | |
经营活动提供的净现金
|
| | | $ | 47,169 | | | | | $ | 70,008 | | | | | $ | 98,385 | | | | | $ | (22,839) | | | | | $ | (28,377) | | |
| | | | | |
变化
|
| ||||||||||||||||||||||||
As of June 30
|
| |
2019
|
| |
2018
|
| |
2017
|
| |
2019/2018
|
| |
2018/2017
|
| |||||||||||||||
| | |
(以千计,比率除外)
|
| |||||||||||||||||||||||||||
现金和现金等价物和短期投资
|
| | | $ | 81,573 | | | | | $ | 79,168 | | | | | $ | 56,083 | | | | | $ | 2,405 | | | | | $ | 23,085 | | |
营运资金
|
| | | | 242,902 | | | | | | 205,651 | | | | | | 198,036 | | | | | | 37,251 | | | | | | 7,615 | | |
流动资产对流动负债的比率
|
| | | | 2.71:1 | | | | | | 2.57:1 | | | | | | 2.81:1 | | | | |
| | | | | |
变化
|
| ||||||||||||||||||||||||
As of June 30
|
| |
2019
|
| |
2018
|
| |
2017
|
| |
2019/2018
|
| |
2018/2017
|
| |||||||||||||||
| | |
(千)
|
| |||||||||||||||||||||||||||
应收账款-贸易
|
| | | $ | 159,022 | | | | | $ | 135,742 | | | | | $ | 125,847 | | | | | $ | 23,280 | | | | | $ | 9,895 | | |
DSO
|
| | | | 70 | | | | | | 58 | | | | | | 58 | | | | |
| | | | | |
变化
|
| ||||||||||||||||||||||||
As of June 30
|
| |
2019
|
| |
2018
|
| |
2017
|
| |
2019/2018
|
| |
2018/2017
|
| |||||||||||||||
| | |
(千)
|
| |||||||||||||||||||||||||||
盘存
|
| | | $ | 198,322 | | | | | $ | 178,170 | | | | | $ | 161,233 | | | | | $ | 20,152 | | | | | $ | 16,937 | | |
| | |
年数
|
| | ||||||||||||||||||||||||||
| | |
在%1内
|
| |
超过1到3
|
| |
超过3至5
|
| |
超过5
|
| |
总计
|
| |||||||||||||||
| | |
(千)
|
| |||||||||||||||||||||||||||
长期债务(包括本期部分)
|
| | | $ | 12,540 | | | | | $ | 218,750 | | | | | $ | — | | | | | $ | — | | | | | $ | 231,290 | | |
循环信贷工具
|
| | | | — | | | | | | 96,000 | | | | | | — | | | | | | — | | | | | | 96,000 | | |
利息支付
|
| | | | 12,100 | | | | | | 22,261 | | | | | | | | | | | | — | | | | | | 34,361 | | |
租赁承诺
|
| | | | 5,815 | | | | | | 7,351 | | | | | | 2,309 | | | | | | 765 | | | | | | 16,240 | | |
与收购相关的注意事项
|
| | | | 70 | | | | | | 140 | | | | | | 140 | | | | | | 140 | | | | | | 490 | | |
其他
|
| | | | 1,990 | | | | | | 792 | | | | | | 198 | | | | | | — | | | | | | 2,980 | | |
合同义务总额
|
| | | $ | 32,515 | | | | | $ | 345,294 | | | | | $ | 2,647 | | | | | $ | 905 | | | | | $ | 381,361 | | |
| | |
宿舍
|
| |
年
|
| ||||||||||||||||||||||||
For the Periods Ended
|
| |
9月30日,
2018 |
| |
12月31日,
2018 |
| |
三月三十一号,
2019 |
| |
六月三十日
2019 |
| |
六月三十日
2019 |
| |||||||||||||||
| | |
(千)
|
| |||||||||||||||||||||||||||
净销售额 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
MFA和其他
|
| | | $ | 87,004 | | | | | $ | 93,054 | | | | | $ | 84,095 | | | | | $ | 86,315 | | | | | $ | 350,468 | | |
营养专科
|
| | | | 26,970 | | | | | | 29,460 | | | | | | 28,227 | | | | | | 28,558 | | | | | | 113,215 | | |
疫苗
|
| | | | 17,215 | | | | | | 17,048 | | | | | | 16,867 | | | | | | 17,161 | | | | | | 68,291 | | |
动物健康
|
| | | $ | 131,189 | | | | | $ | 139,562 | | | | | $ | 129,189 | | | | | $ | 132,034 | | | | | $ | 531,974 | | |
矿质营养
|
| | | | 54,838 | | | | | | 62,319 | | | | | | 60,653 | | | | | | 55,972 | | | | | | 233,782 | | |
性能产品
|
| | | | 14,126 | | | | | | 16,342 | | | | | | 15,894 | | | | | | 15,877 | | | | | | 62,239 | | |
总净销售额
|
| | | | 200,153 | | | | | | 218,223 | | | | | | 205,736 | | | | | | 203,883 | | | | | | 827,995 | | |
销售商品成本
|
| | | | 134,348 | | | | | | 149,579 | | | | | | 140,864 | | | | | | 138,580 | | | | | | 563,371 | | |
毛利
|
| | | | 65,805 | | | | | | 68,644 | | | | | | 64,872 | | | | | | 65,303 | | | | | | 264,624 | | |
销售,一般和管理费用
|
| | | | 42,952 | | | | | | 42,938 | | | | | | 42,304 | | | | | | 53,204 | | | | | | 181,398 | | |
营业收入
|
| | | | 22,853 | | | | | | 25,706 | | | | | | 22,568 | | | | | | 12,099 | | | | | | 83,226 | | |
利息费用,净额
|
| | | | 2,783 | | | | | | 3,015 | | | | | | 2,931 | | | | | | 3,047 | | | | | | 11,776 | | |
外币(收益)损失,净额
|
| | | | (2,635) | | | | | | 2,617 | | | | | | 122 | | | | | | (159) | | | | | | (55) | | |
所得税前收入
|
| | | | 22,705 | | | | | | 20,074 | | | | | | 19,515 | | | | | | 9,211 | | | | | | 71,505 | | |
所得税准备金
|
| | | | 6,391 | | | | | | 5,326 | | | | | | 4,666 | | | | | | 409 | | | | | | 16,792 | | |
净收入
|
| | | $ | 16,314 | | | | | $ | 14,748 | | | | | $ | 14,849 | | | | | $ | 8,802 | | | | | $ | 54,713 | | |
每股净收益 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
基本型
|
| | | $ | 0.40 | | | | | $ | 0.37 | | | | | $ | 0.37 | | | | | $ | 0.22 | | | | | $ | 1.35 | | |
稀释
|
| | | $ | 0.40 | | | | | $ | 0.36 | | | | | $ | 0.37 | | | | | $ | 0.22 | | | | | $ | 1.35 | | |
调整后EBITDA | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
动物健康
|
| | | $ | 35,716 | | | | | $ | 35,925 | | | | | $ | 33,241 | | | | | $ | 31,167 | | | | | $ | 136,049 | | |
矿质营养
|
| | | | 2,563 | | | | | | 4,084 | | | | | | 5,287 | | | | | | 3,778 | | | | | | 15,712 | | |
性能产品
|
| | | | 716 | | | | | | 1,514 | | | | | | 1,330 | | | | | | 1,168 | | | | | | 4,728 | | |
公司
|
| | | | (8,886) | | | | | | (9,918) | | | | | | (9,850) | | | | | | (9,798) | | | | | | (38,452) | | |
调整后EBITDA
|
| | | $ | 30,109 | | | | | $ | 31,605 | | | | | $ | 30,008 | | | | | $ | 26,315 | | | | | $ | 118,037 | | |
净收益与调整后EBITDA的对账
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
净收入
|
| | | $ | 16,314 | | | | | $ | 14,748 | | | | | $ | 14,849 | | | | | $ | 8,802 | | | | | $ | 54,713 | | |
利息费用,净额
|
| | | | 2,783 | | | | | | 3,015 | | | | | | 2,931 | | | | | | 3,047 | | | | | | 11,776 | | |
所得税准备金
|
| | | | 6,391 | | | | | | 5,326 | | | | | | 4,666 | | | | | | 409 | | | | | | 16,792 | | |
折旧摊销
|
| | | | 6,691 | | | | | | 6,841 | | | | | | 6,875 | | | | | | 7,157 | | | | | | 27,564 | | |
EBITDA
|
| | | | 32,179 | | | | | | 29,930 | | | | | | 29,321 | | | | | | 19,415 | | | | | | 110,845 | | |
重组成本
|
| | | | — | | | | | | — | | | | | | — | | | | | | 6,281 | | | | | | 6,281 | | |
股票薪酬
|
| | | | 565 | | | | | | 564 | | | | | | 565 | | | | | | 565 | | | | | | 2,259 | | |
与收购相关的交易成本
|
| | | | — | | | | | | — | | | | | | — | | | | | | 213 | | | | | | 213 | | |
其他
|
| | | | — | | | | | | (1,506) | | | | | | — | | | | | | — | | | | | | (1,506) | | |
外币(收益)损失,净额
|
| | | | (2,635) | | | | | | 2,617 | | | | | | 122 | | | | | | (159) | | | | | | (55) | | |
调整后EBITDA
|
| | | $ | 30,109 | | | | | $ | 31,605 | | | | | $ | 30,008 | | | | | $ | 26,315 | | | | | $ | 118,037 | | |
| | |
宿舍
|
| |
年
|
| ||||||||||||||||||||||||
For the Periods Ended
|
| |
9月30日,
2017 |
| |
12月31日,
2017 |
| |
三月三十一号,
2018 |
| |
六月三十日
2018 |
| |
六月三十日
2018 |
| |||||||||||||||
| | |
(千)
|
| |||||||||||||||||||||||||||
净销售额 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
MFA和其他
|
| | | $ | 79,603 | | | | | $ | 82,018 | | | | | $ | 82,935 | | | | | $ | 92,110 | | | | | $ | 336,666 | | |
营养专科
|
| | | | 30,777 | | | | | | 32,623 | | | | | | 31,366 | | | | | | 28,212 | | | | | | 122,978 | | |
疫苗
|
| | | | 18,461 | | | | | | 18,204 | | | | | | 18,009 | | | | | | 17,409 | | | | | | 72,083 | | |
动物健康
|
| | | $ | 128,841 | | | | | $ | 132,845 | | | | | $ | 132,310 | | | | | $ | 137,731 | | | | | $ | 531,727 | | |
矿质营养
|
| | | | 52,073 | | | | | | 59,616 | | | | | | 62,938 | | | | | | 60,295 | | | | | | 234,922 | | |
性能产品
|
| | | | 12,498 | | | | | | 13,415 | | | | | | 13,660 | | | | | | 13,760 | | | | | | 53,333 | | |
总净销售额
|
| | | | 193,412 | | | | | | 205,876 | | | | | | 208,908 | | | | | | 211,786 | | | | | | 819,982 | | |
销售商品成本
|
| | | | 130,030 | | | | | | 138,957 | | | | | | 139,839 | | | | | | 144,277 | | | | | | 553,103 | | |
毛利
|
| | | | 63,382 | | | | | | 66,919 | | | | | | 69,069 | | | | | | 67,509 | | | | | | 266,879 | | |
销售,一般和管理费用
|
| | | | 40,995 | | | | | | 42,981 | | | | | | 42,577 | | | | | | 41,400 | | | | | | 167,953 | | |
营业收入
|
| | | | 22,387 | | | | | | 23,938 | | | | | | 26,492 | | | | | | 26,109 | | | | | | 98,926 | | |
利息费用,净额
|
| | | | 3,118 | | | | | | 3,050 | | | | | | 3,064 | | | | | | 2,678 | | | | | | 11,910 | | |
外币(收益)损失,净额
|
| | | | 325 | | | | | | (323) | | | | | | (960) | | | | | | (96) | | | | | | (1,054) | | |
所得税前收入
|
| | | | 18,944 | | | | | | 21,211 | | | | | | 24,388 | | | | | | 23,527 | | | | | | 88,070 | | |
所得税准备金
|
| | | | 3,052 | | | | | | 14,179 | | | | | | 4,548 | | | | | | 1,408 | | | | | | 23,187 | | |
净收入
|
| | | $ | 15,892 | | | | | $ | 7,032 | | | | | $ | 19,840 | | | | | $ | 22,119 | | | | | $ | 64,883 | | |
每股净收益 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
基本型
|
| | | $ | 0.40 | | | | | $ | 0.17 | | | | | $ | 0.49 | | | | | $ | 0.55 | | | | | $ | 1.61 | | |
稀释
|
| | | $ | 0.39 | | | | | $ | 0.17 | | | | | $ | 0.49 | | | | | $ | 0.55 | | | | | $ | 1.61 | | |
调整后EBITDA | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
动物健康
|
| | | $ | 33,742 | | | | | $ | 35,036 | | | | | $ | 36,292 | | | | | $ | 36,844 | | | | | $ | 141,914 | | |
矿质营养
|
| | | | 3,716 | | | | | | 5,614 | | | | | | 5,375 | | | | | | 3,878 | | | | | | 18,583 | | |
性能产品
|
| | | | 248 | | | | | | 264 | | | | | | 386 | | | | | | 983 | | | | | | 1,881 | | |
公司
|
| | | | (7,589) | | | | | | (8,436) | | | | | | (8,650) | | | | | | (8,745) | | | | | | (33,420) | | |
调整后EBITDA
|
| | | $ | 30,117 | | | | | $ | 32,478 | | | | | $ | 33,403 | | | | | $ | 32,960 | | | | | $ | 128,958 | | |
净收益与调整后EBITDA的对账
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
净收入
|
| | | $ | 15,892 | | | | | $ | 7,032 | | | | | $ | 19,840 | | | | | $ | 22,119 | | | | | $ | 64,883 | | |
利息费用,净额
|
| | | | 3,118 | | | | | | 3,050 | | | | | | 3,064 | | | | | | 2,678 | | | | | | 11,910 | | |
所得税准备金
|
| | | | 3,052 | | | | | | 14,179 | | | | | | 4,548 | | | | | | 1,408 | | | | | | 23,187 | | |
折旧摊销
|
| | | | 6,644 | | | | | | 6,631 | | | | | | 6,751 | | | | | | 6,917 | | | | | | 26,943 | | |
EBITDA
|
| | | | 28,706 | | | | | | 30,892 | | | | | | 34,203 | | | | | | 33,122 | | | | | | 126,923 | | |
与收购相关的销售商品成本
|
| | | | 249 | | | | | | 1,422 | | | | | | — | | | | | | — | | | | | | 1,671 | | |
与收购相关的应计补偿
|
| | | | 437 | | | | | | 487 | | | | | | 160 | | | | | | 68 | | | | | | 1,152 | | |
与收购相关的交易成本
|
| | | | 400 | | | | | | — | | | | | | — | | | | | | — | | | | | | 400 | | |
与收购相关的其他,净
|
| | | | — | | | | | | — | | | | | | — | | | | | | (468) | | | | | | (468) | | |
股票薪酬
|
| | | | — | | | | | | — | | | | | | — | | | | | | 334 | | | | | | 334 | | |
外币(收益)损失,净额
|
| | | | 325 | | | | | | (323) | | | | | | (960) | | | | | | (96) | | | | | | (1,054) | | |
调整后EBITDA
|
| | | $ | 30,117 | | | | | $ | 32,478 | | | | | $ | 33,403 | | | | | $ | 32,960 | | | | | $ | 128,958 | | |
|
独立注册会计师事务所报告
|
| | | | 81 | | |
|
截至6月30日、2019年、2018年和2017财年的合并运营报表
|
| | | | 83 | | |
|
截至2019年6月30日、2018年和
2017 |
| | | | 84 | | |
|
截至6月30日、2019年和2018年的综合资产负债表
|
| | | | 85 | | |
|
截至6月30日、2019年、2018年和2017财年的现金流量表合并报表*
|
| | | | 86 | | |
|
截至2019年6月30日的会计年度股东权益变动综合报表··
2018 and 2017. |
| | | | 87 | | |
|
截至6月30日、2019年、2018年和2017财年的合并财务报表注释
|
| | | | 88 | | |
For the Year Ended June 30
|
| |
2019
|
| |
2018
|
| |
2017
|
| |||||||||
| | |
(以千计,每股金额除外)
|
| |||||||||||||||
净销售额
|
| | | $ | 827,995 | | | | | $ | 819,982 | | | | | $ | 764,281 | | |
销售商品成本
|
| | | | 563,371 | | | | | | 553,103 | | | | | | 516,038 | | |
毛利
|
| | | | 264,624 | | | | | | 266,879 | | | | | | 248,243 | | |
销售,一般和管理费用
|
| | | | 181,398 | | | | | | 167,953 | | | | | | 150,309 | | |
营业收入
|
| | | | 83,226 | | | | | | 98,926 | | | | | | 97,934 | | |
利息费用,净额
|
| | | | 11,776 | | | | | | 11,910 | | | | | | 14,906 | | |
外币(收益)损失,净额
|
| | | | (55) | | | | | | (1,054) | | | | | | (113) | | |
清偿债务损失
|
| | | | — | | | | | | — | | | | | | 2,598 | | |
所得税前收入
|
| | | | 71,505 | | | | | | 88,070 | | | | | | 80,543 | | |
所得税准备金
|
| | | | 16,792 | | | | | | 23,187 | | | | | | 15,928 | | |
净收入
|
| | | $ | 54,713 | | | | | $ | 64,883 | | | | | $ | 64,615 | | |
每股净收益 | | | | | | | | | | | | | | | | | | | |
基本型
|
| | | $ | 1.35 | | | | | $ | 1.61 | | | | | $ | 1.63 | | |
稀释
|
| | | $ | 1.35 | | | | | $ | 1.61 | | | | | $ | 1.61 | | |
加权平均已发行普通股 | | | | | |||||||||||||||
基本型
|
| | | | 40,412 | | | | | | 40,181 | | | | | | 39,524 | | |
稀释
|
| | | | 40,523 | | | | | | 40,385 | | | | | | 40,042 | | |
For the Year Ended June 30
|
| |
2019
|
| |
2018
|
| |
2017
|
| |||||||||
| | |
(千)
|
| |||||||||||||||
净收入
|
| | | $ | 54,713 | | | | | $ | 64,883 | | | | | $ | 64,615 | | |
衍生工具公允价值变动
|
| | | | (5,580) | | | | | | 2,300 | | | | | | 31 | | |
外币折算调整
|
| | | | (4,127) | | | | | | (23,542) | | | | | | (1,652) | | |
未确认的养老金净收益(亏损)
|
| | | | (1,837) | | | | | | (154) | | | | | | 12,918 | | |
(规定)所得税福利
|
| | | | 1,846 | | | | | | 350 | | | | | | (4,949) | | |
其他综合收益(亏损)
|
| | | | (9,698) | | | | | | (21,046) | | | | | | 6,348 | | |
综合收益
|
| | | $ | 45,015 | | | | | $ | 43,837 | | | | | $ | 70,963 | | |
As of June 30
|
| |
2019
|
| |
2018
|
| ||||||
| | |
(除每股及每股金额外,以千计)
|
| |||||||||
资产 | | | | | | | | | | | | | |
现金及现金等价物
|
| | | $ | 57,573 | | | | | $ | 29,168 | | |
短期投资
|
| | | | 24,000 | | | | | | 50,000 | | |
应收帐款,净额
|
| | | | 159,022 | | | | | | 135,742 | | |
库存,净额
|
| | | | 198,322 | | | | | | 178,170 | | |
其他流动资产
|
| | | | 27,245 | | | | | | 22,381 | | |
流动资产总额
|
| | | | 466,162 | | | | | | 415,461 | | |
财产,厂房和设备,净额
|
| | | | 140,235 | | | | | | 130,108 | | |
无形资产,净
|
| | | | 47,478 | | | | | | 51,978 | | |
商誉
|
| | | | 27,348 | | | | | | 27,348 | | |
其他资产
|
| | | | 45,448 | | | | | | 46,784 | | |
总资产
|
| | | $ | 726,671 | | | | | $ | 671,679 | | |
负债和股东权益 | | | | | | | | | | | | | |
长期债务的当期部分
|
| | | $ | 12,540 | | | | | $ | 12,579 | | |
应付帐款
|
| | | | 73,189 | | | | | | 59,498 | | |
应计费用和其他流动负债
|
| | | | 68,498 | | | | | | 71,144 | | |
流动负债总额
|
| | | | 154,227 | | | | | | 143,221 | | |
循环信贷工具
|
| | | | 96,000 | | | | | | 70,000 | | |
长期债务
|
| | | | 217,635 | | | | | | 229,802 | | |
其他负债
|
| | | | 42,794 | | | | | | 43,702 | | |
负债共计
|
| | | | 510,656 | | | | | | 486,725 | | |
承诺和或有事项(注8) | | | | | | | | | | | | | |
普通股,面值每股0.0001美元;300,000,000 A级
授权股份,发行20,287,574股和19,992,204股 并分别于6月30日、2019年和2018年表现突出; 30,000,000 B类股份授权,20,166,034和 20,365,504股已发行并于2019年6月30日流通股·2019年和 2018年,分别 |
| | | | 4 | | | | | | 4 | | |
优先股,每股面值0.0001美元;授权股票16,000,000股,未发行股票和未发行股票
|
| | | | — | | | | | | — | | |
实收资本
|
| | | | 133,266 | | | | | | 129,873 | | |
留存收益
|
| | | | 168,926 | | | | | | 131,560 | | |
累计其他综合收益(亏损)
|
| | | | (86,181) | | | | | | (76,483) | | |
股东权益总额
|
| | | | 216,015 | | | | | | 184,954 | | |
总负债和股东权益
|
| | | $ | 726,671 | | | | | $ | 671,679 | | |
For the Year Ended June 30
|
| |
2019
|
| |
2018
|
| |
2017
|
| |||||||||
| | |
(千)
|
| |||||||||||||||
经营活动 | | | | | | | | | | | | | | | | | | | |
净收入
|
| | | $ | 54,713 | | | | | $ | 64,883 | | | | | $ | 64,615 | | |
调整净收益与经营活动提供(使用)的现金净额:
|
| | | | | | | | | | | | | | | | | | |
折旧摊销
|
| | | | 27,564 | | | | | | 26,943 | | | | | | 26,001 | | |
债务发行成本摊销和债务折价
|
| | | | 882 | | | | | | 883 | | | | | | 1,015 | | |
股票薪酬
|
| | | | 2,259 | | | | | | 334 | | | | | | — | | |
与采购相关的项目
|
| | | | — | | | | | | 3,908 | | | | | | 2,081 | | |
养老金结算成本
|
| | | | — | | | | | | — | | | | | | 1,702 | | |
递延所得税
|
| | | | (105) | | | | | | 6,389 | | | | | | (28) | | |
外币(收益)损失,净额
|
| | | | (1,899) | | | | | | (635) | | | | | | (867) | | |
其他
|
| | | | (302) | | | | | | 1,181 | | | | | | 765 | | |
清偿债务损失
|
| | | | — | | | | | | — | | | | | | 2,598 | | |
营业资产和负债的变动(扣除业务收购后):
|
| | | | | | | | | | | | | | | | | | |
应收帐款,净额
|
| | | | (23,679) | | | | | | (11,900) | | | | | | (2,765) | | |
库存,净额
|
| | | | (20,982) | | | | | | (24,292) | | | | | | 5,432 | | |
其他流动资产
|
| | | | (7,173) | | | | | | 134 | | | | | | (3,012) | | |
其他资产
|
| | | | (299) | | | | | | (152) | | | | | | (1,504) | | |
应付帐款
|
| | | | 12,092 | | | | | | 2,446 | | | | | | (3,119) | | |
应计费用及其他负债
|
| | | | 4,098 | | | | | | (114) | | | | | | 5,471 | | |
经营活动提供的净现金
|
| | | | 47,169 | | | | | | 70,008 | | | | | | 98,385 | | |
投资活动 | | | | | | | | | | | | | | | | | | | |
购买短期投资
|
| | | | (34,000) | | | | | | (82,000) | | | | | | — | | |
短期投资期限
|
| | | | 60,000 | | | | | | 32,000 | | | | | | — | | |
资本支出
|
| | | | (29,891) | | | | | | (18,548) | | | | | | (20,880) | | |
业务收购
|
| | | | (9,838) | | | | | | (15,000) | | | | | | — | | |
其他,净
|
| | | | (404) | | | | | | (1,064) | | | | | | (1,062) | | |
投资活动使用的现金净额
|
| | | | (14,133) | | | | | | (84,612) | | | | | | (21,942) | | |
融资活动 | | | | | | | | | | | | | | | | | | | |
循环信贷工具借款
|
| | | | 213,000 | | | | | | 225,000 | | | | | | 230,500 | | |
循环信用贷款偿还
|
| | | | (187,000) | | | | | | (220,000) | | | | | | (234,500) | | |
长期债务收益
|
| | | | — | | | | | | — | | | | | | 250,000 | | |
支付长期债务、资本租赁和其他
|
| | | | (12,649) | | | | | | (6,401) | | | | | | (285,527) | | |
签发应付购置单
|
| | | | 3,775 | | | | | | — | | | | | | — | | |
应付购置单付款
|
| | | | (3,775) | | | | | | — | | | | | | — | | |
债务发行成本
|
| | | | — | | | | | | — | | | | | | (3,925) | | |
发行普通股收益
|
| | | | 1,134 | | | | | | 5,699 | | | | | | 5,541 | | |
已支付股息
|
| | | | (18,592) | | | | | | (16,073) | | | | | | (15,827) | | |
筹资活动使用的现金净额
|
| | | | (4,107) | | | | | | (11,775) | | | | | | (53,738) | | |
汇率变动对现金的影响
|
| | | | (524) | | | | | | (536) | | | | | | (227) | | |
现金及现金等价物净增(减)
|
| | | | 28,405 | | | | | | (26,915) | | | | | | 22,478 | | |
期初现金及现金等价物
|
| | | | 29,168 | | | | | | 56,083 | | | | | | 33,605 | | |
期末现金及现金等价物
|
| | | $ | 57,573 | | | | | $ | 29,168 | | | | | $ | 56,083 | | |
补充现金流量信息 | | | | | | | | | | | | | | | | | | | |
已付利息
|
| | | $ | 12,250 | | | | | $ | 11,208 | | | | | $ | 14,600 | | |
已缴纳所得税,净额
|
| | | | 16,215 | | | | | | 15,191 | | | | | | 14,762 | | |
非现金投融资活动 | | | | | | | | | | | | | | | | | | | |
物业、厂房和设备以及资本租赁的增加
|
| | | | 2,890 | | | | | | 8,449 | | | | | | 1,550 | | |
| | |
股份
普普通通 股票 |
| |
普普通通
股票 |
| |
择优
股票 |
| |
实收
资本 |
| |
留用
收益 |
| |
累积
其他 综合 收入(亏损) |
| |
总计
|
| |||||||||||||||||||||
截至2016年6月30日
|
| | | | 39,407,568 | | | | | $ | 4 | | | | | $ | — | | | | | $ | 118,299 | | | | | $ | 33,962 | | | | | $ | (61,785) | | | | | $ | 90,480 | | |
综合收益(亏损)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 64,615 | | | | | | 6,348 | | | | | | 70,963 | | |
股票期权的行使
|
| | | | 468,400 | | | | | | — | | | | | | — | | | | | | 5,541 | | | | | | — | | | | | | — | | | | | | 5,541 | | |
已宣派股息(每股0.40美元)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (15,827) | | | | | | — | | | | | | (15,827) | | |
As of June 30, 2017
|
| | | | 39,875,968 | | | | | $ | 4 | | | | | $ | — | | | | | $ | 123,840 | | | | | $ | 82,750 | | | | | $ | (55,437) | | | | | $ | 151,157 | | |
综合收益(亏损)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 64,883 | | | | | | (21,046) | | | | | | 43,837 | | |
股票期权的行使
|
| | | | 481,740 | | | | | | — | | | | | | — | | | | | | 5,699 | | | | | | — | | | | | | — | | | | | | 5,699 | | |
已宣派股息(每股0.40美元)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (16,073) | | | | | | — | | | | | | (16,073) | | |
股票补偿费用
|
| | | | — | | | | | | — | | | | | | — | | | | | | 334 | | | | | | — | | | | | | — | | | | | | 334 | | |
As of June 30, 2018
|
| | | | 40,357,708 | | | | | $ | 4 | | | | | $ | — | | | | | $ | 129,873 | | | | | $ | 131,560 | | | | | $ | (76,483) | | | | | $ | 184,954 | | |
采用新的收入标准
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 1,245 | | | | | | — | | | | | | 1,245 | | |
综合收益(亏损)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 54,713 | | | | | | (9,698) | | | | | | 45,015 | | |
股票期权的行使
|
| | | | 95,900 | | | | | | — | | | | | | — | | | | | | 1,134 | | | | | | — | | | | | | — | | | | | | 1,134 | | |
已宣派股息(每股0.46美元)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (18,592) | | | | | | — | | | | | | (18,592) | | |
股票补偿费用
|
| | | | — | | | | | | — | | | | | | — | | | | | | 2,259 | | | | | | — | | | | | | — | | | | | | 2,259 | | |
As of June 30, 2019
|
| | | | 40,453,608 | | | | | $ | 4 | | | | | $ | — | | | | | $ | 133,266 | | | | | $ | 168,926 | | | | | $ | (86,181) | | | | | $ | 216,015 | | |
For the Year Ended June 30
|
| |
2019
|
| |
2018
|
| |
2017
|
| |||||||||
净收入
|
| | | $ | 54,713 | | | | | $ | 64,883 | | | | | $ | 64,615 | | |
加权平均股份数-基本
|
| | | | 40,412 | | | | | | 40,181 | | | | | | 39,524 | | |
股票期权和限制性股票单位的稀释效应
|
| | | | 111 | | | | | | 204 | | | | | | 518 | | |
加权平均股数-稀释
|
| | | | 40,523 | | | | | | 40,385 | | | | | | 40,042 | | |
每股净收益 | | | | | |||||||||||||||
基本型
|
| | | $ | 1.35 | | | | | $ | 1.61 | | | | | $ | 1.63 | | |
稀释
|
| | | $ | 1.35 | | | | | $ | 1.61 | | | | | $ | 1.61 | | |
As of July 1, 2018
|
| |
vt.影响,影响
收养 |
| |
Post-adoption
|
| ||||||
其他流动资产
|
| | | $ | 2,100 | | | | | $ | 24,481 | | |
其他资产
|
| | | | 2,325 | | | | | | 49,109 | | |
应计费用和其他流动负债
|
| | | | 343 | | | | | | 71,487 | | |
其他负债
|
| | | | 2,837 | | | | | | 46,539 | | |
留存收益
|
| | | $ | 1,245 | | | | | $ | 132,805 | | |
As of June 30, 2019
|
| |
vt.影响,影响
收养 |
| |
As reported
|
| ||||||
其他流动资产
|
| | | $ | 225 | | | | | $ | 27,245 | | |
其他资产
|
| | | | 225 | | | | | | 45,448 | | |
其他负债
|
| | | | (216) | | | | | | 42,794 | | |
留存收益
|
| | | $ | 666 | | | | | $ | 168,926 | | |
For the Year Ended June 30, 2019
|
| |
vt.影响,影响
收养 |
| |
As reported
|
| ||||||
净销售额
|
| | | $ | 793 | | | | | $ | 827,995 | | |
所得税准备金
|
| | | | 127 | | | | | | 16,792 | | |
净收入
|
| | | $ | 666 | | | | | $ | 54,713 | | |
For the Year Ended June 30
|
| |
2019
|
| |
2018
|
| |
2017
|
| |||||||||
动物健康 | | | | | |||||||||||||||
MFA和其他
|
| | | $ | 350,468 | | | | | $ | 336,666 | | | | | $ | 321,430 | | |
营养专科
|
| | | | 113,215 | | | | | | 122,978 | | | | | | 111,282 | | |
疫苗
|
| | | | 68,291 | | | | | | 72,083 | | | | | | 65,033 | | |
动物卫生总量
|
| | | $ | 531,974 | | | | | $ | 531,727 | | | | | $ | 497,745 | | |
矿质营养
|
| | | | 233,782 | | | | | | 234,922 | | | | | | 218,298 | | |
性能产品
|
| | | | 62,239 | | | | | | 53,333 | | | | | | 48,238 | | |
总计
|
| | | $ | 827,995 | | | | | $ | 819,982 | | | | | $ | 764,281 | | |
For the Year Ended June 30
|
| |
2019
|
| |
2018
|
| |
2017
|
| |||||||||
美国
|
| | | $ | 480,101 | | | | | $ | 490,880 | | | | | $ | 483,794 | | |
拉丁美洲和加拿大
|
| | | | 152,380 | | | | | | 143,231 | | | | | | 113,187 | | |
欧洲、中东和非洲
|
| | | | 105,365 | | | | | | 110,377 | | | | | | 95,838 | | |
亚太
|
| | | | 90,149 | | | | | | 75,494 | | | | | | 71,462 | | |
总计
|
| | | $ | 827,995 | | | | | $ | 819,982 | | | | | $ | 764,281 | | |
For the Year Ended June 30
|
| |
2019
|
| |
2018
|
| |
2017
|
| |||||||||
利息费用,净额 | | | | | |||||||||||||||
定期贷款
|
| | | $ | 8,553 | | | | | $ | 8,321 | | | | | $ | 11,482 | | |
循环信贷工具
|
| | | | 3,748 | | | | | | 2,777 | | | | | | 2,897 | | |
债务发行成本摊销和债务折价
|
| | | | 882 | | | | | | 883 | | | | | | 1,015 | | |
与收购相关的应计利息
|
| | | | — | | | | | | 1,085 | | | | | | 1,373 | | |
其他
|
| | | | 494 | | | | | | 537 | | | | | | 105 | | |
利息费用
|
| | | | 13,677 | | | | | | 13,603 | | | | | | 16,872 | | |
利息(收入)
|
| | | | (1,901) | | | | | | (1,693) | | | | | | (1,966) | | |
| | | | $ | 11,776 | | | | | $ | 11,910 | | | | | $ | 14,906 | | |
|
For the Year Ended June 30
|
| |
2019
|
| |
2018
|
| |
2017
|
| |||||||||
折旧摊销 | | | | | |||||||||||||||
财产、厂房和设备折旧
|
| | | $ | 21,423 | | | | | $ | 21,044 | | | | | $ | 19,916 | | |
无形资产摊销
|
| | | | 6,092 | | | | | | 5,851 | | | | | | 5,950 | | |
其他资产摊销
|
| | | | 49 | | | | | | 48 | | | | | | 135 | | |
| | | | $ | 27,564 | | | | | $ | 26,943 | | | | | $ | 26,001 | | |
For the Year Ended June 30
|
| |
2019
|
| |
2018
|
| |
2017
|
| |||||||||
研发支出
|
| | | $ | 12,083 | | | | | $ | 9,998 | | | | | $ | 9,442 | | |
|
As of June 30
|
| |
2019
|
| |
2018
|
| ||||||
应收帐款,净额 | | | | ||||||||||
应收贸易账款
|
| | | $ | 163,464 | | | | | $ | 141,999 | | |
呆账备抵
|
| | | | (4,442) | | | | | | (6,257) | | |
| | | | $ | 159,022 | | | | | $ | 135,742 | | |
|
As of June 30
|
| |
2019
|
| |
2018
|
| |
2017
|
| |||||||||
呆账备抵 | | | | | |||||||||||||||
期初余额
|
| | | $ | 6,257 | | | | | $ | 6,428 | | | | | $ | 4,953 | | |
坏账准备
|
| | | | (201) | | | | | | 166 | | | | | | 1,412 | | |
汇率变动的影响
|
| | | | 38 | | | | | | (215) | | | | | | 159 | | |
坏账核销
|
| | | | (1,500) | | | | | | — | | | | | | — | | |
坏账回收
|
| | | | (152) | | | | | | (122) | | | | | | (96) | | |
期末余额
|
| | | $ | 4,442 | | | | | $ | 6,257 | | | | | $ | 6,428 | | |
|
As of June 30
|
| |
2019
|
| |
2018
|
| ||||||
盘存 | | | | ||||||||||
原料
|
| | | $ | 64,441 | | | | | $ | 62,373 | | |
在制品
|
| | | | 10,699 | | | | | | 14,731 | | |
成品
|
| | | | 123,182 | | | | | | 101,066 | | |
| | | | $ | 198,322 | | | | | $ | 178,170 | | |
|
As of June 30
|
| |
2019
|
| |
2018
|
| ||||||
财产,厂房和设备,净额 | | | | ||||||||||
土地
|
| | | $ | 10,152 | | | | | $ | 10,140 | | |
建筑和改善
|
| | | | 71,036 | | | | | | 68,769 | | |
机械设备
|
| | | | 252,097 | | | | | | 227,092 | | |
| | | | | 333,285 | | | | | | 306,001 | | |
累计折旧
|
| | | | (193,050) | | | | | | (175,893) | | |
| | | | $ | 140,235 | | | | | $ | 130,108 | | |
As of June 30
|
| |
加权-
平均值 使用寿命 (年) |
| |
2019
|
| |
2018
|
| |||||||||
无形资产,净 | | | | | |||||||||||||||
成本 | | | | | |||||||||||||||
工艺
|
| | | | 13 | | | | | $ | 71,016 | | | | | $ | 69,475 | | |
产品注册,营销和分发权
|
| | | | 9 | | | | | | 17,858 | | | | | | 17,902 | | |
客户关系
|
| | | | 13 | | | | | | 12,194 | | | | | | 12,211 | | |
商品名称、商标及其他
|
| | | | 5 | | | | | | 2,740 | | | | | | 2,740 | | |
正在进行的研究和开发
|
| | | | | | | | | | 1,800 | | | | | | 1,800 | | |
| | | | | | | | | | | 105,608 | | | | | | 104,128 | | |
累计摊销 | | | | | |||||||||||||||
工艺
|
| | | | | | | | | | (29,333) | | | | | | (23,937) | | |
产品注册,营销和分发权
|
| | | | | | | | | | (17,811) | | | | | | (17,902) | | |
客户关系
|
| | | | | | | | | | (8,282) | | | | | | (7,614) | | |
商品名称、商标及其他
|
| | | | | | | | | | (2,704) | | | | | | (2,697) | | |
| | | | | | | | | | | (58,130) | | | | | | (52,150) | | |
| | | | | | | | | | $ | 47,478 | | | | | $ | 51,978 | | |
|
As of June 30
|
| |
2019
|
| |
2018
|
| ||||||
商誉前滚 | | | | ||||||||||
期初余额
|
| | | $ | 27,348 | | | | | $ | 23,982 | | |
采办
|
| | | | — | | | | | | 5,642 | | |
翻译
|
| | | | — | | | | | | (2,276) | | |
期末余额
|
| | | $ | 27,348 | | | | | $ | 27,348 | | |
As of June 30
|
| |
2019
|
| |
2018
|
| ||||||
其他资产 | | | | ||||||||||
权益法投资
|
| | | $ | 4,196 | | | | | $ | 3,944 | | |
保险投资
|
| | | | 5,431 | | | | | | 5,235 | | |
递延融资费
|
| | | | 1,531 | | | | | | 2,042 | | |
递延所得税
|
| | | | 16,770 | | | | | | 15,424 | | |
存款
|
| | | | 7,024 | | | | | | 6,692 | | |
赔偿资产
|
| | | | 3,000 | | | | | | 3,000 | | |
衍生工具公允价值
|
| | | | — | | | | | | 5,078 | | |
其他
|
| | | | 7,496 | | | | | | 5,369 | | |
| | | | $ | 45,448 | | | | | $ | 46,784 | | |
As of June 30
|
| |
2019
|
| |
2018
|
| ||||||
应计费用和其他流动负债 | | | | ||||||||||
员工相关
|
| | | $ | 28,298 | | | | | $ | 27,333 | | |
佣金和回扣
|
| | | | 8,397 | | | | | | 7,341 | | |
保险相关
|
| | | | 1,279 | | | | | | 1,168 | | |
专业费用
|
| | | | 5,212 | | | | | | 4,350 | | |
所得税和其他税
|
| | | | 6,067 | | | | | | 3,610 | | |
与收购相关的注意事项
|
| | | | — | | | | | | 12,845 | | |
重组成本
|
| | | | 3,590 | | | | | | — | | |
其他
|
| | | | 15,655 | | | | | | 14,497 | | |
| | | | $ | 68,498 | | | | | $ | 71,144 | | |
As of June 30
|
| |
2019
|
| |
2018
|
| ||||||
其他负债 | | | | ||||||||||
美国养老金计划
|
| | | $ | 3,934 | | | | | $ | 2,910 | | |
国际退休计划
|
| | | | 5,133 | | | | | | 4,644 | | |
补充退休福利、递延补偿和其他
|
| | | | 7,605 | | | | | | 10,792 | | |
长期所得税和递延所得税
|
| | | | 8,978 | | | | | | 9,729 | | |
重组成本
|
| | | | 2,000 | | | | | | — | | |
其他长期负债
|
| | | | 15,144 | | | | | | 15,627 | | |
| | | | $ | 42,794 | | | | | $ | 43,702 | | |
|
As of June 30
|
| |
2019
|
| |
2018
|
| ||||||
累计其他综合收益(亏损) | | | | ||||||||||
衍生工具
|
| | | $ | (594) | | | | | $ | 4,986 | | |
外币折算调整
|
| | | | (71,225) | | | | | | (67,098) | | |
未确认的养老金净收益(亏损)
|
| | | | (20,050) | | | | | | (18,213) | | |
(规定)衍生工具所得税利益
|
| | | | 148 | | | | | | (1,241) | | |
(拨备)长期公司间投资所得税福利
|
| | | | 8,166 | | | | | | 8,166 | | |
(规定)养老金收益(损失)所得税福利
|
| | | | (2,626) | | | | | | (3,083) | | |
| | | | $ | (86,181) | | | | | $ | (76,483) | | |
As of June 30
|
| |
2019
|
| |
2018
|
| ||||||
期限A贷款到期6月·2022
|
| | | $ | 231,250 | | | | | $ | 243,750 | | |
资本化租赁义务
|
| | | | 40 | | | | | | 118 | | |
| | | | | 231,290 | | | | | | 243,868 | | |
未摊销债务发行成本和债务贴现
|
| | | | (1,115) | | | | | | (1,487) | | |
| | | | | 230,175 | | | | | | 242,381 | | |
减:当前到期日
|
| | | | (12,540) | | | | | | (12,579) | | |
| | | | $ | 217,635 | | | | | $ | 229,802 | | |
|
For the Year Ended June 30
|
| | |||||
2020
|
| | | $ | 12,540 | | |
2021
|
| | | | 18,750 | | |
2022
|
| | | | 200,000 | | |
总计
|
| | | $ | 231,290 | | |
| | |
2019
|
| |
2018
|
| | | | | | | |
2019
|
| |
2018
|
| ||||||||||||
As of June 30
|
| |
授权股份
|
| |
面值
|
| |
已发行和已发行股份
|
| |||||||||||||||||||||
优先股
|
| | | | 16,000,000 | | | | | | 16,000,000 | | | | | $ | 0.0001 | | | | | | — | | | | | | — | | |
普通股-A类
|
| | | | 300,000,000 | | | | | | 300,000,000 | | | | | $ | 0.0001 | | | | | | 20,287,574 | | | | | | 19,992,204 | | |
普通股-B类
|
| | | | 30,000,000 | | | | | | 30,000,000 | | | | | $ | 0.0001 | | | | | | 20,166,034 | | | | | | 20,365,504 | | |
| | |
RSU
|
| |
授予日期
公允价值 每RSU·共享 |
| |
授予日期
公允价值 |
| |||||||||
授予基于性能的RSU
May 2018 |
| | | | 200,000 | | | | | $ | 19.63 | | | | | $ | 3,926 | | |
2018年5月授予基于时间的RSU
|
| | | | 50,000 | | | | | $ | 41.10 | | | | | $ | 2,055 | | |
杰出的6月30日,2019年和2018年
|
| | | | 250,000 | | | | | $ | 23.92 | | | | | $ | 5,981 | | |
| | |
选择权
股份 |
| |
加权平均
行使价格 每股 |
| ||||||
杰出,2018年6月30日
|
| | | | 95,900 | | | | | $ | 11.83 | | |
已行使
|
| | | | (95,900) | | | | | $ | 11.83 | | |
杰出,6月30日,2019年
|
| | | | — | | | | | $ | — | | |
For the Year Ended June 30
|
| |
2019
|
| |
2018
|
| ||||||
预计福利义务的变化 | | | | ||||||||||
年初预计福利义务
|
| | | $ | 61,557 | | | | | $ | 63,260 | | |
利息成本
|
| | | | 2,407 | | | | | | 2,157 | | |
已付福利
|
| | | | (1,758) | | | | | | (2,196) | | |
精算(收益)损失
|
| | | | 6,321 | | | | | | (1,664) | | |
年终预计福利义务
|
| | | $ | 68,527 | | | | | $ | 61,557 | | |
|
For the Year Ended June 30
|
| |
2019
|
| |
2018
|
| ||||||
计划资产变动 | | | | ||||||||||
年初计划资产公允价值
|
| | | $ | 58,648 | | | | | $ | 57,110 | | |
计划资产实际收益
|
| | | | 6,860 | | | | | | 965 | | |
雇主供款
|
| | | | 842 | | | | | | 2,768 | | |
已付福利
|
| | | | (1,757) | | | | | | (2,195) | | |
年终计划资产公允价值
|
| | | $ | 64,593 | | | | | $ | 58,648 | | |
年终资金状况
|
| | | $ | (3,934) | | | | | $ | (2,909) | | |
For the Year Ended June 30
|
| |
2019
|
| |
2018
|
| ||||||
累计与养老金计划相关的其他综合收入(亏损)
|
| | | | | | | | | | | | |
期初余额
|
| | | $ | (18,213) | | | | | $ | (18,059) | | |
精算净损失摊销
|
| | | | 465 | | | | | | 453 | | |
本期净精算(亏损)收益
|
| | | | (2,302) | | | | | | (607) | | |
净变化
|
| | | | (1,837) | | | | | | (154) | | |
期末余额
|
| | | $ | (20,050) | | | | | $ | (18,213) | | |
For the Year Ended June 30
|
| |
2019
|
| |
2018
|
| |
2017
|
| |||||||||
服务成本-年内获得的收益
|
| | | $ | — | | | | | $ | — | | | | | $ | 845 | | |
利益义务的利息成本
|
| | | | 2,407 | | | | | | 2,157 | | | | | | 2,045 | | |
计划资产预期收益
|
| | | | (2,842) | | | | | | (3,236) | | | | | | (3,389) | | |
精算净损失摊销
|
| | | | 465 | | | | | | 453 | | | | | | 672 | | |
削减费用
|
| | | | — | | | | | | — | | | | | | 16 | | |
结算费用
|
| | | | — | | | | | | — | | | | | | 1,702 | | |
定期养老金费用净额
|
| | | $ | 30 | | | | | $ | (626) | | | | | $ | 1,891 | | |
|
For the Year Ended June 30
|
| |
2019
|
| |
2018
|
| |
2017
|
| |||||||||
服务成本贴现率
|
| | | | 不适用 | | | | | | 不适用 | | | | | | 4.0% | | |
利息成本贴现率
|
| | | | 3.1% | | | | | | 3.9% | | | | | | 3.2% | | |
计划资产预期收益率
|
| | | | 4.9% | | | | | | 5.6% | | | | | | 6.1% | | |
年终福利义务贴现率
|
| | | | 3.6% | | | | | | 4.2% | | | | | | 3.9% | | |
For the Year Ended June 30
|
| | |||||
2020
|
| | | $ | 2,599 | | |
2021
|
| | | | 2,878 | | |
2022
|
| | | | 3,113 | | |
2023
|
| | | | 3,318 | | |
2024
|
| | | | 3,474 | | |
2025–2029
|
| | | | 18,828 | | |
| | |
靶子
分配 |
| |
计划资产百分比
|
| |||||||||
For the Year Ended June 30
|
| |
2020
|
| |
2019
|
| |
2018
|
| ||||||
债务证券
|
| |
57%–77%
|
| | | | 67% | | | | | | 63% | | |
股权证券
|
| |
18%–38%
|
| | | | 28% | | | | | | 26% | | |
全球资产配置/风险平价(1)
|
| |
0%–15%
|
| | | | 4% | | | | | | 10% | | |
其他
|
| |
0%–10%
|
| | | | 1% | | | | | | 1% | | |
| | |
公允价值计量使用
|
| |||||||||||||||||||||
As of June 30, 2019
|
| |
Level 1
|
| |
Level 2
|
| |
Level 3
|
| |
Total
|
| ||||||||||||
现金及现金等价物
|
| | | $ | 215 | | | | | $ | — | | | | | $ | — | | | | | $ | 215 | | |
共同集体基金 | | | | | | ||||||||||||||||||||
全球大盘股
|
| | | | — | | | | | | 13,995 | | | | | | 4,016 | | | | | | 18,011 | | |
固定收益证券
|
| | | | — | | | | | | 43,288 | | | | | | — | | | | | | 43,288 | | |
全球资产配置/风险平价
|
| | | | — | | | | | | 1,446 | | | | | | — | | | | | | 1,446 | | |
其他 | | | | | | ||||||||||||||||||||
全球资产配置/风险平价
|
| | | | — | | | | | | — | | | | | | 1,447 | | | | | | 1,447 | | |
其他
|
| | | | — | | | | | | — | | | | | | 186 | | | | | | 186 | | |
| | | | $ | 215 | | | | | $ | 58,729 | | | | | $ | 5,649 | | | | | $ | 64,593 | | |
|
| | |
公允价值计量使用
|
| |||||||||||||||||||||
As of June 30, 2018
|
| |
Level 1
|
| |
Level 2
|
| |
Level 3
|
| |
Total
|
| ||||||||||||
现金及现金等价物
|
| | | $ | 428 | | | | | $ | — | | | | | $ | — | | | | | $ | 428 | | |
共同集体基金 | | | | | | ||||||||||||||||||||
全球大盘股
|
| | | | — | | | | | | 11,632 | | | | | | 3,811 | | | | | | 15,443 | | |
固定收益证券
|
| | | | — | | | | | | 36,671 | | | | | | — | | | | | | 36,671 | | |
全球资产配置/风险平价
|
| | | | — | | | | | | 2,957 | | | | | | — | | | | | | 2,957 | | |
其他 | | | | | | ||||||||||||||||||||
全球资产配置/风险平价
|
| | | | — | | | | | | — | | | | | | 2,881 | | | | | | 2,881 | | |
其他
|
| | | | — | | | | | | — | | | | | | 268 | | | | | | 268 | | |
| | | | $ | 428 | | | | | $ | 51,260 | | | | | $ | 6,960 | | | | | $ | 58,648 | | |
3级资产公允价值变动
|
| |
2019
|
| |
2018
|
| ||||||
期初余额
|
| | | $ | 6,960 | | | | | $ | 15,959 | | |
赎回
|
| | | | (4,336) | | | | | | (9,901) | | |
购货
|
| | | | 2,800 | | | | | | — | | |
公允价值变动
|
| | | | 225 | | | | | | 902 | | |
期末余额
|
| | | $ | 5,649 | | | | | $ | 6,960 | | |
For the Year Ended June 30
|
| |
2019
|
| |
2018
|
| |
2017
|
| |||||||||
国内
|
| | | $ | 2,331 | | | | | $ | 19,819 | | | | | $ | 18,015 | | |
外方
|
| | | | 69,174 | | | | | | 68,251 | | | | | | 62,528 | | |
所得税前收入
|
| | | $ | 71,505 | | | | | $ | 88,070 | | | | | $ | 80,543 | | |
|
For the Year Ended June 30
|
| |
2019
|
| |
2018
|
| |
2017
|
| |||||||||
当前拨备(福利): | | | | | |||||||||||||||
联邦制
|
| | | $ | (459) | | | | | $ | 81 | | | | | $ | 383 | | |
州和地方
|
| | | | 102 | | | | | | 1,744 | | | | | | 724 | | |
外方
|
| | | | 16,603 | | | | | | 15,268 | | | | | | 14,839 | | |
流动总拨备
|
| | | | 16,246 | | | | | | 17,093 | | | | | | 15,946 | | |
递延拨备(福利): | | | | | |||||||||||||||
联邦制
|
| | | | 858 | | | | | | 2,746 | | | | | | 4,675 | | |
州和地方
|
| | | | 432 | | | | | | 2,156 | | | | | | 251 | | |
外方
|
| | | | (691) | | | | | | 769 | | | | | | (833) | | |
估价免税额变动-国外
|
| | | | (53) | | | | | | 423 | | | | | | (4,111) | | |
递延准备金总额(福利)
|
| | | | 546 | | | | | | 6,094 | | | | | | (18) | | |
所得税准备金
|
| | | $ | 16,792 | | | | | $ | 23,187 | | | | | $ | 15,928 | | |
For the Year Ended June 30
|
| |
2019
|
| |
2018
|
| |
2017
|
| |||||||||
联邦所得税税率
|
| | | | 21.0% | | | | | | 28.1% | | | | | | 35.0% | | |
州和地方税,扣除联邦利益
|
| | | | 0.6 | | | | | | 1.5 | | | | | | 0.9 | | |
国外所得税税率
|
| | | | 6.9 | | | | | | (1.5) | | | | | | (6.8) | | |
国外激励税率
|
| | | | (2.8) | | | | | | (3.3) | | | | | | (3.1) | | |
国外所得税国内税
|
| | | | — | | | | | | — | | | | | | 2.7 | | |
不确定税收状况的变化
|
| | | | (1.0) | | | | | | 1.1 | | | | | | 1.6 | | |
永久项目
|
| | | | 0.6 | | | | | | 0.5 | | | | | | (0.9) | | |
员工股票期权的行使
|
| | | | (0.4) | | | | | | (4.3) | | | | | | (3.8) | | |
全球无形低税收入
|
| | | | 0.8 | | | | | | — | | | | | | — | | |
强制征收税法通行费
|
| | | | (0.5) | | | | | | 0.5 | | | | | | — | | |
国内递延税金资产减少
|
| | | | — | | | | | | 2.6 | | | | | | — | | |
减少国外递延税金资产
|
| | | | — | | | | | | 1.3 | | | | | | — | | |
承认联邦税收抵免
|
| | | | (1.1) | | | | | | — | | | | | | — | | |
承认外国税收抵免
|
| | | | (1.4) | | | | | | (0.7) | | | | | | — | | |
从累计的其他综合收入重新分类
|
| | | | — | | | | | | 0.6 | | | | | | — | | |
放行外国估价津贴
|
| | | | — | | | | | | — | | | | | | (5.1) | | |
其他
|
| | | | (0.8) | | | | | | (0.1) | | | | | | (0.7) | | |
有效税率
|
| | | | 23.5% | | | | | | 26.3% | | | | | | 19.8% | | |
As of June 30
|
| |
2019
|
| |
2018
|
| ||||||
递延税项资产: | | | | ||||||||||
员工相关应计
|
| | | $ | 5,735 | | | | | $ | 4,952 | | |
盘存
|
| | | | 4,766 | | | | | | 3,953 | | |
环境修复
|
| | | | 1,128 | | | | | | 1,341 | | |
净营业亏损结转-国内
|
| | | | 902 | | | | | | 1,577 | | |
净营业亏损结转-国外
|
| | | | 3,703 | | | | | | 3,243 | | |
其他
|
| | | | 6,302 | | | | | | 9,986 | | |
| | | | | 22,536 | | | | | | 25,052 | | |
估价津贴
|
| | | | (808) | | | | | | (861) | | |
| | | | | 21,728 | | | | | | 24,191 | | |
递延税金负债: | | | | ||||||||||
财产、厂房、设备和无形资产
|
| | | | (6,071) | | | | | | (8,957) | | |
其他
|
| | | | (772) | | | | | | (1,906) | | |
| | | | | (6,843) | | | | | | (10,863) | | |
递延税金净资产
|
| | | $ | 14,885 | | | | | $ | 13,328 | | |
As of June 30
|
| |
2019
|
| |
2018
|
| ||||||
其他资产
|
| | | $ | 16,770 | | | | | $ | 15,424 | | |
其他负债
|
| | | | (1,885) | | | | | | (2,096) | | |
| | | | $ | 14,885 | | | | | $ | 13,328 | | |
As of June 30
|
| |
2019
|
| |
2018
|
| |
2017
|
| |||||||||
期初余额
|
| | | $ | 861 | | | | | $ | 438 | | | | | $ | 4,614 | | |
所得税准备金
|
| | | | (53) | | | | | | 423 | | | | | | (4,111) | | |
净营业损失利用率
|
| | | | — | | | | | | — | | | | | | (65) | | |
期末余额
|
| | | $ | 808 | | | | | $ | 861 | | | | | $ | 438 | | |
As of June 30
|
| |
2019
|
| |
2018
|
| |
2017
|
| |||||||||
未确认的税收优惠-期初
|
| | | $ | 7,000 | | | | | $ | 6,553 | | | | | $ | 4,946 | | |
税位变动-本期
|
| | | | 528 | | | | | | 1,749 | | | | | | 1,490 | | |
税收状况变化-前期,减去与税务当局的结算净额
|
| | | | (317) | | | | | | (994) | | | | | | — | | |
诉讼时效的失效
|
| | | | (1,053) | | | | | | — | | | | | | (391) | | |
翻译
|
| | | | 185 | | | | | | (308) | | | | | | 508 | | |
未确认的税收优惠-期末
|
| | | | 6,343 | | | | | | 7,000 | | | | | | 6,553 | | |
利息和罚金-期末
|
| | | | 750 | | | | | | 633 | | | | | | 449 | | |
与不确定税相关的总负债
职位 |
| | | $ | 7,093 | | | | | $ | 7,633 | | | | | $ | 7,002 | | |
For the Year Ended June 30
|
| |
资本
租约 |
| |
不可取消
经营租赁 |
| ||||||
2020
|
| | | $ | 40 | | | | | $ | 5,815 | | |
2021
|
| | | | — | | | | | | 4,160 | | |
2022
|
| | | | — | | | | | | 3,191 | | |
2023
|
| | | | — | | | | | | 1,445 | | |
2024
|
| | | | | | | | | | 865 | | |
此后
|
| | | | — | | | | | | 765 | | |
最低租赁付款总额
|
| | | $ | 40 | | | | | $ | 16,241 | | |
Instrument
|
| |
树篱
|
| |
概念
金额 June 30, 2019 |
| |
固形
资产负债表 |
| |
资产(负债)
公允价值截至 |
| |||||||||
|
六月三十日
2019 |
| |
六月三十日
2018 |
| |||||||||||||||||
选项
|
| |
巴西皇马呼叫
|
| |
R$ 43,000
|
| |
(1)
|
| | | $ | 413 | | | | | $ | 71 | | |
选项
|
| |
巴西雷亚尔看跌期权
|
| |
R$ 43,000
|
| |
(1)
|
| | | $ | (30) | | | | | $ | — | | |
互换
|
| | 利率互换 | | |
$150,000
|
| |
其他资产
(其他负债) |
| | | $ | (977) | | | | | $ | 5,078 | | |
For the Year Ended June 30
|
| |
OCI记录的收益(损失)
|
| |
合并确认损益
经营报表 |
| |
合并报表
操作行项目合计 |
| |||||||||||||||||||||||||||||||||
Instrument
|
| |
Hedge
|
| |
2019
|
| |
2018
|
| |
固形
声明 运筹学 |
| |
2019
|
| |
2018
|
| |
2019
|
| |
2018
|
| ||||||||||||||||||
选项 | | |
巴西皇马呼叫
|
| | | $ | 475 | | | | | $ | (2,778) | | | |
销售商品成本
|
| | | $ | 1,069 | | | | | $ | 3,136 | | | | | $ | 563,371 | | | | | $ | 553,103 | | |
互换
|
| |
利率互换
|
| | | $ | (6,055) | | | | | $ | 5,078 | | | |
利息费用,净额
|
| | | $ | — | | | | | $ | — | | | | | $ | 11,776 | | | | | $ | 11,910 | | |
As of June 30
|
| |
2019
|
| |
2018
|
| ||||||||||||||||||
| | |
1级
|
| |
标高·2
|
| |
1级
|
| |
标高·2
|
| ||||||||||||
短期投资
|
| | | $ | 24,000 | | | | | $ | — | | | | | $ | 50,000 | | | | | $ | — | | |
衍生品资产(负债)
|
| | | $ | — | | | | | $ | 383 | | | | | $ | — | | | | | $ | 71 | | |
利率掉期(负债)
|
| | | $ | — | | | | | $ | (977) | | | | | $ | — | | | | | $ | 5,078 | | |
For the Year Ended June 30
|
| |
2019
|
| |
2018
|
| |
2017
|
| |||||||||
净销售额 | | | | | | | | | | | | | | | | | | | |
动物健康
|
| | | $ | 531,974 | | | | | $ | 531,727 | | | | | $ | 497,745 | | |
矿质营养
|
| | | | 233,782 | | | | | | 234,922 | | | | | | 218,298 | | |
性能产品
|
| | | | 62,239 | | | | | | 53,333 | | | | | | 48,238 | | |
总线段
|
| | | $ | 827,995 | | | | | $ | 819,982 | | | | | $ | 764,281 | | |
折旧摊销 | | | | | | | | | | | | | | | | | | | |
动物健康
|
| | | $ | 22,312 | | | | | $ | 21,447 | | | | | $ | 20,132 | | |
矿质营养
|
| | | | 2,319 | | | | | | 2,371 | | | | | | 2,332 | | |
性能产品
|
| | | | 1,127 | | | | | | 1,029 | | | | | | 939 | | |
总线段
|
| | | $ | 25,758 | | | | | $ | 24,847 | | | | | $ | 23,403 | | |
调整后EBITDA | | | | | | | | | | | | | | | | | | | |
动物健康
|
| | | $ | 136,049 | | | | | $ | 141,914 | | | | | $ | 130,261 | | |
矿质营养
|
| | | | 15,712 | | | | | | 18,583 | | | | | | 17,426 | | |
性能产品
|
| | | | 4,728 | | | | | | 1,881 | | | | | | 2,057 | | |
总线段
|
| | | $ | 156,489 | | | | | $ | 162,378 | | | | | $ | 149,744 | | |
所得税前收入调节至
调整后EBITDA |
| | | | | | | | | | | | | | | | | | |
所得税前收入
|
| | | $ | 71,505 | | | | | $ | 88,070 | | | | | $ | 80,543 | | |
利息费用,净额
|
| | | | 11,776 | | | | | | 11,910 | | | | | | 14,906 | | |
折旧和摊销-总细分
|
| | | | 25,758 | | | | | | 24,847 | | | | | | 23,403 | | |
折旧和摊销-公司
|
| | | | 1,806 | | | | | | 2,096 | | | | | | 2,598 | | |
公司成本
|
| | | | 38,452 | | | | | | 33,420 | | | | | | 29,625 | | |
重组成本
|
| | | | 6,281 | | | | | | — | | | | | | — | | |
股票薪酬
|
| | | | 2,259 | | | | | | 334 | | | | | | — | | |
与收购相关的销售商品成本
|
| | | | — | | | | | | 1,671 | | | | | | — | | |
与收购相关的应计补偿
|
| | | | — | | | | | | 1,152 | | | | | | 1,680 | | |
与收购相关的交易成本
|
| | | | 213 | | | | | | 400 | | | | | | 1,274 | | |
与收购相关的其他,净
|
| | | | — | | | | | | (468) | | | | | | (972) | | |
其他
|
| | | | (1,506) | | | | | | — | | | | | | — | | |
养老金结算成本
|
| | | | — | | | | | | — | | | | | | 1,702 | | |
保险结算收益
|
| | | | — | | | | | | — | | | | | | (7,500) | | |
外币(收益)损失,净额
|
| | | | (55) | | | | | | (1,054) | | | | | | (113) | | |
清偿债务损失
|
| | | | — | | | | | | — | | | | | | 2,598 | | |
调整后的EBITDA-总细分市场
|
| | | $ | 156,489 | | | | | $ | 162,378 | | | | | $ | 149,744 | | |
As of June 30
|
| |
2019
|
| |
2018
|
| ||||||
可识别资产 | | | | | | | | | | | | | |
动物健康
|
| | | $ | 508,864 | | | | | $ | 455,704 | | |
矿质营养
|
| | | | 67,662 | | | | | | 69,779 | | |
性能产品
|
| | | | 32,886 | | | | | | 24,040 | | |
总线段
|
| | | | 609,412 | | | | | | 549,523 | | |
公司
|
| | | | 117,259 | | | | | | 122,156 | | |
总计
|
| | | $ | 726,671 | | | | | $ | 671,679 | | |
As of June 30
|
| |
2019
|
| |
2018
|
| ||||||
财产,厂房和设备,净额 | | | | | | | | | | | | | |
美国
|
| | | $ | 54,999 | | | | | $ | 55,268 | | |
以色列
|
| | | | 52,434 | | | | | | 45,055 | | |
巴西
|
| | | | 19,647 | | | | | | 19,653 | | |
其他
|
| | | | 13,155 | | | | | | 10,132 | | |
| | | | $ | 140,235 | | | | | $ | 130,108 | | |
| | | | 菲布罗动物卫生公司 | | |||
| August 27, 2019 | | | 依据: | | |
/s/Jack C.Bendheim
杰克·C·本德海姆
董事长、总裁兼首席执行官 |
|
| | | | 菲布罗动物卫生公司 | | |||
| August 27, 2019 | | | 依据: | | |
/s/Jack C.Bendheim
杰克·C·本德海姆
董事长、总裁兼首席执行官 |
|
| August 27, 2019 | | | 依据: | | |
/s/Richard G.Johnson
理查德·G·约翰逊
首席财务官 |
|
| August 27, 2019 | | | 依据: | | |
/s/Daniel M.Bendheim
丹尼尔·M·本德海姆
董事兼执行副总裁, 企业战略 |
|
| August 27, 2019 | | | 依据: | | |
/s/Jonathan Bendheim
乔纳森本海姆(Jonathan Bendheim)
马奇地区董事兼总裁兼以色列业务部总经理 |
|
| August 27, 2019 | | | 依据: | | |
/s/杰拉尔德·K·卡尔森(Gerald K.Carlson)
杰拉尔德·K·卡尔森
主任 |
|
| August 27, 2019 | | | 依据: | | |
/s/E.Thomas Corcoran
E.托马斯·科克伦(E.Thomas Corcoran)
主任 |
|
| August 27, 2019 | | | 依据: | | |
/s/Sam Gejdenon
Sam Gejdenon
主任 |
|
| August 27, 2019 | | | 依据: | | |
/s/George Gunn
乔治·冈恩(George Gunn)
主任 |
|
| August 27, 2019 | | | 依据: | | |
/s/Mary Lou Malanoski
玛丽·卢·马拉诺斯基
主任 |
|
| August 27, 2019 | | | 依据: | | |
/s/Carol A.Wrenn
Carol A.Wrenn
主任 |
|
| Exhibit 2.1* | | | MVP Laboratory,Inc.、Mary Lou Chapek、AVP、LLC和Phibro Animal Health Corporation之间签订的2016年1月12日的资产购买协议(通过引用Phibro Animal Health Corporation于2016年5月9日提交的Form 10-Q季度报告的附件2.1合并)。 | |
| Exhibit 3.1 | | | 修改和恢复菲布罗动物健康公司的公司注册证书(通过引用Phibro动物健康公司于2014年5月13日提交的10-Q表格季度报告的附件3.1并入(文件号:·001-36410)。 | |
| Exhibit 3.2 | | | 修改和恢复菲布罗动物卫生公司的章程(参照菲布罗动物健康公司于2014年5月13日提交的10-Q表格季度报告的附件3.2合并(文件号001-36410)。 | |
| Exhibit 4.1 | | | Phibro Animal Health Corporation与BFI Co.,LLC之间的注册权协议,截至2014年4月16日(通过引用Phibro Animal Health Corporation于2014年3月提交的表格S-1/A的注册声明中的附件4.9(文件号:333-194467)合并)。 | |
| Exhibit 4.2 | | | 根据1934年“证券交易法”第12节登记的证券描述。 | |
| Exhibit 10.1 | | | Phibro Animal Health Corporation,Bank of America,N.A.与每家贷款人之间于2017年6月29日签订的信贷协议(参照Phibro Animal Health Corporation于2017年6月29日提交给证券交易委员会的Form 8-K当前报告的附件10.1合并)。 (文件编号001-36410)。 (*)* | |
| Exhibit 10.2 | | | 无保护租赁协议,日期为2011年1月26日,由撒玛利亚地毯有限公司和ABIC生物实验室有限公司达成(翻译自希伯来语)(参照菲布罗动物卫生公司2014年3月10日提交的表格S-1注册声明的附件10.17(文件编号333-194467)合并)。 | |
| Exhibit 10.3 | | | 2014年3月27日签订的雇佣协议,由Jack C.Bendheim和Phibro Animal Health Corporation(通过引用Phibro Animal Health Corporation于2014年3月31日提交的表格S-1/A的注册声明的附件10.18(文件编号:333-194467)合并)。 | |
| Exhibit 10.4 | | | 2008年5月2日拉里·L·米勒和菲布罗动物健康公司之间的就业邀请函,包括截至2008年5月2日的保密和保密、员工发明以及不竞争和非招标协议(通过引用2014年3月10日提交的菲布罗动物健康公司表格S-1注册声明的附件10.20(文件编号:333-194467)合并)。 (*)* | |
| Exhibit 10.5 | | | 澄清雇佣要约修正案,日期为2009年12月21日,由Larry L.Miller和Phibro Animal Health Corporation(通过引用Phibro Animal Health Corporation于2014年3月提交的表格S-1注册声明的附件10.21(文件编号:333-194467)合并)。 | |
| Exhibit 10.6 | | | 2011年12月15日拉里·L·米勒和菲布罗动物健康公司之间的就业邀请函修正案(通过引用菲布罗动物健康公司2014年3月10日提交的表格S-1的注册声明(文件编号333-194467)的附件10.22合并)。 | |
| Exhibit 10.7 | | | Phibro Animal Health Corporation 2008年激励计划(参照Phibro Animal Health Corporation于2014年3月10日提交的表格S-1注册声明的附件10.23(文件号:333-194467)合并)。 | |
| Exhibit 10.8 | | | 菲布罗动物健康公司管理激励计划(参照2014年3月31日提交的表S-1/A(文件编号:333-194467)的菲布罗动物健康公司注册声明的附件10.24并入)。 | |
| Exhibit 10.9 | | | 菲布罗动物健康公司退休收入和递延补偿计划,截至2009年4月15日修订和重述(通过引用2014年3月10日提交的表S-1的菲布罗动物健康公司注册声明的附件10.25(文件编号:333-194467)并入)。 (*)* | |
| Exhibit 10.10 | | | Phibro Animal Health Corporation执行收入递延补偿协议,日期为1990年3月1日(参照Phibro Animal Health Corporation于2014年3月10日提交的表格S-1的注册声明中的附件10.26合并)(文件编号333-194467)。 | |
| Exhibit 10.11 | | | 2009年股票期权授予协议表格(参照菲布罗动物卫生公司2014年3月提交的表格S-1/A的登记声明(文件编号:333-194467)的附件10.28合并)。 | |
| Exhibit 10.12 | | | 2013年股票期权授予协议表格(参照2014年3月31日提交的Phibro Animal Health Corporation关于表格S-1/A的登记声明(文件编号333-194467)的附件10.29并入)。 | |
| Exhibit 10.13 | | | 赔偿协议表(参照Phibro Animal Health Corporation于2014年4月提交的表S-1/A的注册声明的附件10.32合并(文件号333-194467)。 | |
| Exhibit 10.14* | | | MJ Biologics,Inc.于2015年1月20日签署的知识产权购买协议,以及MJ Biologics,Inc.之间的知识产权购买协议和Phibro Animal Health Corporation(通过引用Phibro Animal Health Corporation的季度报告Form 10-Q(2015年5月11日提交给证券交易委员会)的附件10.33合并) | |
| Exhibit 10.15* | | | MJ Biologics,Inc.于2015年1月20日起草的知识产权购买协议的第一修正案于2018年7月31日生效。和Phibro Animal Health Corporation(通过引用Phibro Animal Health Corporation的季度报告Form 10-Q(2018年11月6日提交给证券交易委员会)的附件10.18合并)。 | |
| Exhibit 10.16 | | | Phibro Animal Health Corporation与Dean J.Warras于2016年6月16日签署的推广信协议(通过引用Phibro Animal Health Corporation于2017年8月30日提交给证券交易委员会的Form 10-K 2017年年度报告的附件10.38并入本文(文件号:NO.001-36410)。(*) | |
| Exhibit 10.17 | | | Phibro Animal Health Corporation和Dean J.Warras之间的保留信协议,日期为2016年8月1日(通过引用Phibro Animal Health Corporation于2017年8月30日提交给证券交易委员会的Form 10-K的2017年年度报告的附件10.39并入本文)。 (文件号·001-36410)。 | |
| Exhibit 10.18 | | | 限制性股票单位奖励协议表格(通过参考菲布罗动物健康公司当前报告Form 8-K的附件10.2并入,表格8-K于2018年5月·7日提交给证券交易委员会(文件号:·13-1840497)。 | |
| Exhibit 10.19 | | | 执行长期激励协议,日期为2015年5月11日,由菲布罗动物健康公司和理查德·G·约翰逊公司和理查德·G·约翰逊公司之间签订,日期为2016年8月1日,菲布罗动物健康公司和迪恩·J·瓦拉斯之间的保留信件协议(通过引用附件·10.34并入菲布罗动物健康公司2015年10-K表格年度报告,于2015年9月10日提交给证券交易委员会(文件编号001-36410) ,该协议由Phibro Animal Health Corporation和Richard G.Johnson签署,日期为2016年8月1日,Phibro Animal Health Corporation和DeanJ.Warras之间的协议(文件编号:001-36410) | |
| Exhibit 10.20 | | | 由Thomas G.Dagger和Phibro Animal Health Corporation签署,日期为2006年11月3日的雇佣协议。 | |
| Exhibit 10.21 | | | 修订雇佣协议,日期为2009年11月16日,由Thomas G.Dagger和Phibro Animal Health Corporation共同签署。 | |
| Exhibit 10.22 | | | 由Thomas G.Dagger和Phibro Animal Health Corporation共同签署,日期为2011年12月16日的雇佣协议修正案。 | |
| Exhibit 21.1 | | | 菲布罗动物卫生公司子公司名单 | |
| Exhibit 23 | | | 独立注册会计师事务所同意 | |
| Exhibit 31.1 | | | 首席执行官-根据2002年Sarbanes-Oxley法案第302节进行认证 | |
| Exhibit 31.2 | | | 首席财务官-根据2002年Sarbanes-Oxley法案第302节进行认证 | |
| Exhibit 32.1** | | | 首席执行官-根据2002年Sarbanes-Oxley法案第906节进行认证 | |
| Exhibit 32.2** | | | 首席财务官-根据2002年Sarbanes-Oxley法案第906节进行认证 | |
|
附件101.INS*
|
| | XBRL实例文档 | |
|
附件101.SCH*
|
| | XBRL分类扩展架构文档 | |
|
附件101.CAL*
|
| | XBRL分类扩展计算链接库文档 | |
|
附件101.DEF*
|
| | XBRL分类扩展定义链接库文档 | |
|
附件101.LAB*
|
| | XBRL分类扩展标签链接库文档 | |
|
附件101.PRE*
|
| | XBRL Taxonomy Extension Presentation Linkbase文档 | |